pyrroles has been researched along with Neoplasms in 595 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (3.19) | 18.7374 |
| 1990's | 3 (0.50) | 18.2507 |
| 2000's | 144 (24.20) | 29.6817 |
| 2010's | 343 (57.65) | 24.3611 |
| 2020's | 86 (14.45) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, X; Qin, S; Yang, M; Yin, Y; Yu, F; Zhang, H; Zhang, J; Zhang, Y; Zhu, M | 1 |
| Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D | 1 |
| Cao, Y; Feng, Q; Geng, S; Liu, C; Pan, X; Shou, P; Tian, J; Wang, K; Wu, A; Wu, Y; Xing, J; Yin, C; Yu, Z; Zhou, B | 1 |
| Langova, V; Nguyen, SM; Thomas, PM; Todd, JE; Tzannes, S; White, J | 1 |
| Bauer, S; Carpio, C; Cassier, PA; Chatterjee, M; Chromik, J; de Vos, F; DeAngelo, DJ; Esteve, J; Fabre, C; Ferretti, S; Guerreiro, N; Halilovic, E; Kiladjian, JJ; Lin, CC; Mariconti, L; Meille, C; Minami, H; Mous, R; Pereira, B; Radhakrishnan, R; Steeghs, N; Stein, EM; Suarez, C; Tai, D; Yamamoto, N | 1 |
| Fan, L; Guo, R; Han, J; Sun, X; Wang, J; Wang, Z; Xi, J; Zhu, C | 1 |
| Bagheri, H; Ghanei, M; Ghazvini, A; Khoshsafar, H; Taheri, N | 1 |
| Jung, BH; Kong, M; Lee, H; Park, J; Yang, JS; Yoon, N | 1 |
| Chen, X; Gong, X; Ji, T; Liu, X; Yeleswaram, S | 1 |
| Hu, H; Li, R; Ren, J; Wei, J; Wong, CY; Xu, Q; Xu, Z; Yang, Z; Zhang, L | 1 |
| Bertelli, F; Chivers, S; Hartley, JA; Havenith, KE; Hogg, P; Janghra, N; Reinert, HW; Tyrer, P; van Berkel, PH; Zammarchi, F | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Amin, M; Bagegni, NA; Baggstrom, MQ; Devarakonda, S; Gao, F; Kraft, K; Liang, C; Morgensztern, D; O-Toole, M; Park, H; Ratner, L; Selvaggi, G; Wang-Gillam, A; Waqar, SN | 1 |
| Greenberg, J; Healey, JH; Hsu, C; LaCreta, F; Lasseter, KC; Marbury, TC; Stacchiotti, S; Tap, WD; Xu, LA; Zahir, H | 1 |
| Berlin, JD; Ding, K; Garrido-Laguna, I; Geschwindt, R; Leopold, L; LoRusso, PM; Luke, JJ; Mansfield, AS; Messersmith, WA; Naing, A; Nemunaitis, JJ; Powderly, JD; Sahebjam, S; Smith, M | 1 |
| Fatahala, SS; Mansour, YEE; Mohamed, MS; Sabry, JY | 1 |
| Bilgin, E; Duran, E; Ertenli, İ; Kalyoncu, U; Kiraz, S; Ünaldı, E | 1 |
| Chen, T; Hou, L; Huang, Y; Jiang, T; Ma, Z; Shi, Z; Wang, S; Yang, F | 1 |
| Cui, X; Jia, F; Li, Y; Pan, Z; Wang, X; Wu, Y | 1 |
| Cheng, Y; Gui, Y; Wu, K; Zhang, Y; Zou, T | 1 |
| Chen, T; Huang, C; Li, H; Liu, Y; Mei, L; Ou, M; Tang, J; Wang, T; Wu, M; Yi, Y; Yu, M; Zeng, W | 1 |
| Aubé, J; Baljinnyam, B; Bryant-Connah, M; Davis, D; De, S; Dextras, C; Dutta, D; Ferrer, M; Frankowski, KJ; Henderson, MJ; Huang, S; Jadhav, A; Kabir, M; Li, D; Lin, YH; Marugan, JJ; Mathews Griner, LA; Norton, J; Patnaik, S; Rudloff, U; Schoenen, FJ; Shah, P; Simeonov, A; Southall, N; Titus, S; Wachsmuth, LM; Wang, A; Wang, C; Wang, F; Williams, J; Xu, X; Zheng, W; Zhu, E | 1 |
| Du, F; Li, Q; Liu, J; Liu, S; Mao, H; Wu, Y; Xu, X; Yang, M; Zhu, J; Zou, S | 1 |
| Bikinieva, F; Boichuk, S; Galembikova, A; Mustafin, I; Ryzkin, S; Zykova, S | 1 |
| Dai, H; Hu, L; Li, M; Tian, S; Xie, J; Yan, L; Zhang, H | 1 |
| Cao, Y; Chen, Z; Ran, H | 1 |
| Cai, Z; Cui, S; Dai, S; Dong, Y; Lin, N; Liu, P; Shi, J; Tong, B; Wu, X | 1 |
| Gao, M; Liu, K; Qian, J; Tang, BZ; Zhang, Y; Zhou, Z | 1 |
| Hathout, RM | 1 |
| Chen, T; Guan, J; Li, H; Li, Q; Li, W; Liang, H; Mei, L; Wang, X; Wang, Y; Wu, X; Yang, M; Ye, F; Zeng, W; Zhang, F | 1 |
| Du, YW; Liu, FR; Liu, JH; Qiu, MZ; Shi, YX; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, F; Xu, RH; Yu, QQ; Zhang, Y; Zhao, HY | 1 |
| Aizawa, F; Ando-Matsuoka, R; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Maruo, A; Miyata, K; Niimura, T; Sakaguchi, S; Sakajiri, Y; Sawada, R; Shibata, T; Takaoka, M; Yagi, K; Yamanishi, Y; Zamami, Y | 1 |
| Li, X; Liu, Z; Sui, C; Tan, R; Xu, W | 1 |
| Fujiwara, Y; Furukawa, M; Hara, H; Ioka, T; Ji, T; Kuboki, Y; Lihou, C; Mizuno, N; Shimizu, T; Takahashi, S; Takahashi, Y; Takeuchi, S; Tian, C; Ueno, M | 1 |
| Chen, Y; Feng, W; Guo, J; Hu, Z; Li, T; Miao, Q; Song, F; Wang, Z; Wu, C | 1 |
| Brachi, G; Geng, H; Grigsby, CL; Li, X; Lupton, EJ; Ma, Y; Stevens, MM; Stuckey, DJ; Sun, R; Zhou, K | 1 |
| Cao, D; Lai, B; Ran, X; Tang, H; Wang, L | 1 |
| An, B; Ding, H; Gai, S; Gao, Y; He, F; Song, S; Yang, M; Yang, P; Zhang, X | 1 |
| Brana, I; Brown, RJ; Doger, B; Galvao, V; Genta, S; Gu, J; Hansen, AR; Hernández, T; Kalota, A; Lauring, J; Lenox, L; Mehta, J; Mistry, P; Moreno, V; Pastore, F; Patel, B; Patel, MR; Preis, M; Spreafico, A; Vieito, M; Wang, JS | 1 |
| Dong, YB; Feng, J; He, ZL; Shao, YQ; Sun, YY; Wang, Y; Yang, SP; Zhai, YN | 1 |
| Naing, A | 1 |
| Hu, X; Li, C; Lin, W; Liu, S; Xie, Z; Zhang, W | 1 |
| Beaufils, F; Bohnacker, T; Borsari, C; Dall'Asen, A; Fabbro, D; Hebeisen, P; Hillmann, P; Jackson, E; Langlois, JB; Melone, A; Rageot, D; Sele, AM; Wymann, MP | 1 |
| Buchmann, J; Calderón, M; Laufer, J; Molina, M; Theune, LE; Wedepohl, S | 1 |
| Blacque, O; Chao, H; Gasser, G; Karges, J | 1 |
| Blackwood, L; Harper, A; Mason, S | 1 |
| Burvenich, IJG; Harris, MA; Hawkins, CJ; Parker, BS; Rigopoulos, A; Scott, AM; Shekhar, TM; Spurling, A; Walkley, CR; Zanker, D | 1 |
| Goh, CC; Liu, B; Liu, J; Ng, LG; Wang, S | 1 |
| Dekhne, A; Doshi, A; Gangjee, A; Hou, Z; Matherly, LH; O'Connor, C; Xiang, W | 1 |
| Barry, C; Betancourt, O; Blot, V; Coronella, J; D'Hooge, F; Fujita, R; Galvan, D; Gymnopoulos, M; Hartley, JA; Howard, PW; Lieuw, V; Newman, R; Nguyen, S; Pardo, R; Patel, N; Snedden, J; Stewart, C; Vijayakrishnan, B; Villicana, J; Wojciak, J; Wong, E | 1 |
| Bychko, A; Byelinska, I; Dziubenko, N; Hurmach, V; Khilya, O; Kuznietsova, H; Lynchak, O; Milokhov, D; Rybalchenko, V | 1 |
| Ferraldeschi, R; Gordon, MS; Jueliger, S; Keer, H; LoRusso, PM; Mita, AC; Mita, MM; Oganesian, A; Papadopoulos, KP; Su, XY; Tolcher, AW | 1 |
| Bjelic, S; Friedman, R; Georgoulia, PS | 1 |
| Felten, A; Hahn, SJ; Klein, HF; Kleindl, PJ; Leamon, CP; Nicoson, J; Parham, GL; Qi, L; Reddy, J; Reno, D; Santhapuram, HKR; Vaughn, JF; Vlahov, IR; Wang, K; You, F; Zou, N | 1 |
| Jagtap, SV; Rasal, NK; Sonawane, RB | 1 |
| Hanazono, K; Hoshino, Y; Hosoya, K; Izumi, Y; Takagi, S; Yamazaki, H | 1 |
| Akiyoshi, H; Mie, K; Miura, N; Nishida, H; Tanaka, T; Yamazaki, H | 1 |
| Bowman, K; Burke, KA; Burn, TC; Collier, P; Covington, M; Diamond, S; DiMatteo, D; Feldman, P; Gardiner, C; Hansbury, M; He, X; Hollis, G; Huber, R; Klabe, R; Koblish, H; Liu, PCC; Ruggeri, B; Rupar, M; Scherle, P; Soloviev, M; Volgina, A; Wen, X; Wu, L; Wynn, R; Yao, W; Yeleswaram, S; Zhang, Y | 1 |
| Duan, T; Huang, H; Lu, Y; Ma, H; Peng, A; Shi, Q; Wen, K; Wu, L; Wu, X | 1 |
| Dou, H; Gao, M; Hu, Q; Huang, W; Leng, T; Liu, L | 1 |
| Hartley, JA | 2 |
| Knudsen, ES; Kumarasamy, V; Roberts, PJ; Witkiewicz, AK | 1 |
| Chan, G; Ciorba, MA; Lawendy, N; Lichtenstein, GR; Nduaka, CI; Panés, J; Pedersen, RD; Quirk, D; Rogler, G; Su, C; Thorpe, AJ | 1 |
| Dong, S; Fan, H; Hu, W; Ji, J; Reddy, AGK; Sajjad, F; Xing, D; You, Q | 1 |
| Babar, DA; Chopra, S; Kalari, S; Karale, UB; Kaul, G; Makane, VB; Misra, S; Rekha, EM; Rode, HB; Shukla, M; Sriram, D; Vamshi Krishna, E | 1 |
| Awadasseid, A; Jiang, SK; Liang, J; Sugiyama, H; Wu, YL; Xiong, XQ; Xu, L; Zhang, M; Zhang, W; Zhao, XY | 1 |
| Akakuru, OU; Dar, GI; Iqbal, MZ; Li, J; Li, Y; Liu, C; Nosike, EI; Qian, K; Wu, A; Xing, J; Yang, G; Zhang, Z | 1 |
| Babiker, HM; Chandana, SR; Mahadevan, D | 1 |
| Chen, J; Duan, W; Hu, Y; Li, Y; Liu, H; Ren, W; Shen, A; Wei, A; Xie, Z; Zhang, J; Zhang, M; Zhang, Z | 1 |
| Aydın, EB; Aydın, M; Sezgintürk, MK | 1 |
| De, A; Gopal, MB; Laxman, K; Mishra, SK; Ravikanth, M; Reddy, BPK; Robinson, A; Srivastava, R | 1 |
| Kasper, B | 1 |
| Nguyen, VN; Yan, Y; Yoon, J; Zhao, J | 1 |
| Abida, W; Brownstein, S; Drilon, A; Gounder, MM; Groover, A; Harding, JJ; Hyman, DM; Janku, F; Lacouture, ME; Lezcano, C; Li, BT; Liu, D; Offin, M; Sullivan, RJ; Torrisi, JM; Varterasian, M; Welsch, D; Wu, J | 1 |
| George, SM; Kandasubramanian, B; McIntyre, R; Tandon, S | 1 |
| Bando, T; Maeda, R; Sugiyama, H | 1 |
| Akakuru, OU; Iqbal, ZM; Li, Y; Li, Z; Liu, C; Nosike, EI; Pan, C; Wu, A; Xing, J; Xu, C; Zhang, Z; Zheng, J | 1 |
| Chan, E; Grierson, PM; Huffman, J; Liang, C; Liu, J; Lockhart, AC; Morton, A; Pedersen, KS; Picus, J; Roth, BJ; Tan, B; Wang-Gillam, A | 1 |
| Kida, Y; Koshikawa, N; Nagase, H; Shinozaki, Y; Takenaga, K; Tsuji, K; Watanabe, T; Yasui, N | 1 |
| DuBois, SG; Khosravan, R; Verschuur, AC; Wang, E; Wetmore, C | 1 |
| Bouakaz, A; Chen, J; Feng, Y; Qin, D; Wan, M; Wu, D; Zhang, L; Zhu, H | 1 |
| Abebe, M; Abozen, T; Alabanza, PL; Ameni, G; Aseffa, A; Balcha, TT; Baric, RS; Belay, M; Berg, S; Brown, AJ; Chandran, A; Cohen, MS; Coombs, RW; Degli-Angeli, EJ; Demaret, J; Dong, C; Dragavon, JA; Duke, ER; Eltayeb, O; Eron, JJ; Fang, L; Fischer, WA; Forrest, S; Goecker, EA; Harris, KA; Hong, S; Hudgens, MG; Huggett, JF; Jolliffe, DA; Jones, GM; Keys, J; Krajewski, TJ; Li, B; Li, L; Loftis, AJ; Manwandu, H; Martineau, AR; Martineau, HM; Mayito, J; Mollan, KR; Morse, CG; Nikolayevskyy, V; Noursadeghi, M; O'Sullivan, DM; Painter, W; Premkumar, L; Reece, ST; Sheahan, TP; Shuang, S; Szewczyk, LJ; Tayachew, D; Tegegn, M; Tirfie, EA; Tulu, B; Vordermeier, M; Wang, Q; Wang, X; Wohl, DA; Wolfe, CR; Won, JJ; Younis, S; Zewude, A | 1 |
| Cui, X; Fang, F; Lee, CS; Lu, G; Shen, D; Tian, S; Wan, Y; Wang, H; Xiao, Y; Xiong, Y; Zhang, J | 1 |
| Abdel-Wahab, O; Bradley, RK; Cho, H; Chow, A; Chowell, D; Cui, D; De Neef, E; Diaz, LA; Durham, BH; Elhanati, Y; Erickson, C; Gabel, AM; Ghosh, A; Gigoux, M; Greenbaum, B; Hogg, SJ; Jin, J; Knorr, DA; Liu, J; Lu, B; Lu, SX; Merghoub, T; Molina, H; Rhodes, MC; Rousseau, B; Sabio, E; Shah, H; Shen, Y; Singer, M; Taylor, RE; Thomas, JD; Wang, E; Wolchok, JD; Xie, A; Zamarin, D | 1 |
| Apostolidi, M; Gassaway, BM; Gaule, P; Muthusamy, V; Rimm, DL; Rinehart, J; Vathiotis, IA | 1 |
| Lee, BH; Lee, SB; Moon, S; Muniyappan, S | 1 |
| Annweiler, C; Cao, Z; Kwok, HF; Li, X; Liu, W; Mu, C; Sabatier, JM; Sun, F; Wu, Y; Xie, Y; Xu, J | 1 |
| Lin, Z; Liu, JY; Wang, S; Weng, XL; Yang, DC; Zhang, HX | 1 |
| Cheung, SYA; Cullberg, M; Delff, P; Dota, C; Maroj, B; Parkinson, J; Rekić, D; Schiavon, G; Voronova, V | 1 |
| Boss, MK; LaRue, SM; Leary, D; Martin, T; Prebble, AR; Thamm, DH; Weishaar, KM | 1 |
| Ataklti, GY; Choi, J; Doan, VHM; Ly, CD; Mondal, S; Nguyen, VT; Oh, J; Park, S; Vo, TMT; Vu, DD | 1 |
| Sebastian, J | 1 |
| Abernethy, DR; Barnett-Griness, O; Gronich, N; Lavi, I; Rennert, G; Saliba, W | 1 |
| Borkin, D; Chaudhary, A; DeCrescenzo, G; Degrado, S; Dimitrov, DS; Feng, Y; Hilton, MB; Jain, N; Keller, JR; Klarmann, KD; Li, J; Morris, H; Morris, K; Saha, S; Scheiermann, J; Seaman, S; Smith, SW; St Croix, B; Swing, DA; Szot, C; Tessarollo, L; Wang, Y; Welsch, D; Yang, MY; Zhang, XM; Zhu, Z; Zudaire, E | 1 |
| Crawford, E; Curry, W; Gupton, JT; Harrison, A; Hoerrner, M; Huff, E; Juekun, W; Kellogg, GE; Kimmel, M; Lescalleet, K; Lounsbury, K; Mooberry, SL; Moore-Stoll, V; Obaidullah, AJ; Ortolani, J; Patteson, J; Rohena, CC; Shimozono, A; Sikorski, JA; Telang, N; Yeudall, S | 1 |
| Goel, Y; Kumar, A; Pandey, SK; Singh, SM; Singh, VK; Yadav, S | 1 |
| Ambrose, H; Bando, H; Banerji, U; Barrett, JC; Baselga, J; Bedard, PL; Berger, MF; Bouvier, N; Chandarlapaty, S; Chang, MT; Dean, EJ; Donoghue, MTA; Dougherty, B; El-Khoueiry, AB; Erinjeri, JP; Foxley, A; Hyman, DM; Lindemann, JPO; McEwen, R; Mita, A; Pass, M; Pérez-Fidalgo, JA; Reichel, JB; Schellens, JHM; Schiavon, G; Selcuklu, SD; Smyth, LM; Solit, DB; Soumerai, TE; Taylor, BS; Torrisi, J; Westin, SN | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Ai, X; Fu, L; Hao, P; Li, L; Wei, P; Zhang, J; Zhou, J | 1 |
| Cook, SJ; Gilley, R; Sale, MJ; Stuart, K | 1 |
| Aparna, HS; Atreya, HS; Harsha Raj, M; Rashmi, KC; Salimath, BP | 1 |
| Higginbotham, ML; Hocker, SE; Wouda, RM | 1 |
| Chang, K; Chen, H; Fang, X; Gao, D; Li, D; Men, X; Wu, C; Yin, S; Yuan, Z; Zhang, J; Zhang, X; Zhou, L | 1 |
| Cai, Y; Chen, P; Dong, X; Liang, P; Si, W; Tang, Q; Zhang, Q | 1 |
| Byun, S; Lee, E; Lee, KW | 1 |
| Chen, J; Hu, Y; Li, X; Li, Y; Liu, H; Peng, Y; Sun, Y; Xu, J; Yin, G; Zhong, S | 1 |
| Meng, L; Ren, Y; Shao, Y; Wang, D; Yu, D | 1 |
| Darwish, M; Dela Cruz-Chuh, J; Flygare, JA; Gregson, SJ; Gunzner-Toste, J; Howard, PW; Kang, GD; Kozak, KR; Lau, J; Lewis Phillips, GD; Li, G; Masterson, LA; Ohri, R; Pillow, TH; Polson, A; Raab, H; Safina, BS; Spencer, SD; Wei, B; Yu, SF | 1 |
| Kanatharana, P; Kangkamano, T; Limbut, W; Numnuam, A; Thavarungkul, P; Vilaivan, T | 1 |
| Bharathiraja, S; Bui, NQ; Jang, B; Jung, WK; Kim, YM; Lee, KD; Manivasagan, P; Oh, J; Phan, TTV; Santha Moorthy, M | 1 |
| Berger, EP; Fox, LE; Johannes, CM; Post, GS; Rothchild, G; Shiu, KB; Wetzel, S | 1 |
| Cuccarese, MF; Kim, E; Kohler, RH; Miller, MA; Pittet, MJ; Plotkin, AL; Prytyskach, M; Weissleder, R | 1 |
| Balkman, CE; Cawley, JR; Hume, KR; Rizzo, VL | 1 |
| Cao, H; Gao, Y; Jiang, X; Liu, Y; Qu, Z; Sun, H | 1 |
| Felten, A; Hahn, SJ; Klein, HF; Kleindl, PJ; Leamon, CP; Nelson, M; Nicoson, J; Parham, GL; Qi, L; Reddy, JA; Santhapuram, HK; Vaughn, JF; Vetzel, M; Vlahov, IR; Wang, K; You, F | 1 |
| Abel Mahedi Mohamed, H; Nielsen, CEN; Schiodt, M | 1 |
| Abdel-Mogib, M; Al-Mourabit, A; Atanasov, AG; Bishayee, A; El-Demerdash, A; Hooper, JNA | 1 |
| Dragovich, PS; Hop, CECA; Khojasteh, SC; Kozak, KR; Ma, Y; Pillow, TH; Polson, AG; Sadowsky, JD; Su, D; Xu, K; Yu, SF; Zhang, D | 1 |
| Abouzid, KAM; Adel, M; Lasheen, DS; Serya, RAT | 2 |
| Cai, Y; Dong, X; Fan, L; Tang, Q; Wang, C; Wu, X; Zhang, Q | 1 |
| Abrahmsen, LB; Green, JA; Von Euler, M | 1 |
| Ao, L; Chen, J; Ding, Z; Fang, L; Li, H; Liu, K; Liu, X; Pan, Z; Shao, X; Su, W; Sun, H; Tan, Y; Wang, R; Wang, W; Wu, C; Zhang, J | 1 |
| Bailey, C; Banerji, U; Casson, E; Cripps, D; Cullberg, M; Dean, E; Evans, S; Foxley, A; Jimenez, B; Krebs, MG; Lawrence, P; Lindemann, J; Rugman, P; Schellens, JHM; Taylor, N; Turner, G; van Brummelen, E; Yates, J | 1 |
| Ge, D; Liu, X; Liu, Y; Shi, W; Su, H; Sun, Y | 1 |
| Estilo, CL; Huryn, JM; Liang, STY; Owosho, AA; Sax, AZ; Wu, K; Yom, SK | 1 |
| Chi, W; Ferber, G; Jackson, J; Janku, F; Li, BT; Mendzelevski, B; Sager, PT; Sullivan, RJ; Welsch, D; Weng, O | 1 |
| Garofalo, A; Grande, F; Ioele, G; Occhiuzzi, MA; Ragno, G | 1 |
| Inoue, T; Koshikawa, N; Lin, J; Matsuo, N; Mori, Y; Nagase, H; Ozaki, T; Shimozato, O; Shinozaki, Y; Takatori, A; Watanabe, T | 1 |
| Almeida, RG; Baiju, TV; Brito, LM; Cavalcanti, BC; da Silva Júnior, EN; de Simone, CA; Namboothiri, INN; Pessoa, C; Sivanandan, ST | 1 |
| Ayyanaar, S; Kesavan, MP; Kotla, NG; Kumar, GGV; Rajagopal, G; Rajesh, J; Sivaraman, G; Webster, TJ | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Chun, S; Hwang, TI; Joshi, MK; Kim, BS; Kim, CS; Maharjan, B; Oh, JM; Park, CH; Tiwari, AP | 1 |
| Hu, X; Qin, H; Xing, D; Yan, H; Yang, J; Zhai, S | 1 |
| Bakar-Ates, F; Karakas, B; Kilic-Kurt, Z; Kütük, Ö | 1 |
| Grant, FM; Gyori, D; Hawkins, PT; Lim, EL; Okkenhaug, K; Roychoudhuri, R; Shuttleworth, SJ; Spensberger, D; Stephens, LR | 1 |
| Balkman, CE; Hume, KR; Piscoya, SL | 1 |
| Andrs, M; Gorecki, L; Havelek, R; Jun, D; Korabecny, J; Polednikova, M; Pospisilova, M; Rezacova, M; Seifrtova, M; Tichy, A; Vejrychova, K | 1 |
| Chapeau, EA; Cortes-Cros, M; Durand, EY; Ferretti, S; Fuchs, J; Furet, P; Gaulis, S; Guerreiro, N; Halilovic, E; Hofmann, F; Holzer, P; Jeay, S; Jensen, MR; Jullion, A; Kallen, J; Kauffmann, A; Kerr, G; Kuriakose, E; Murakami, M; Romanet, V; Ruetz, S; Sellers, WR; Stachyra, TM; Sterker, D; Wartmann, M; Wiesmann, M; Würthner, J | 1 |
| Berndt, S; Cancho-Grande, Y; Greven, S; Griebenow, N; Johannes, S; Lerchen, HG; Mahlert, C; Rebstock, AS; Sommer, A; Stelte-Ludwig, B; Terjung, C; Wittrock, S | 1 |
| Pan, H; Sun, SK; Wang, X; Zhang, C | 1 |
| Azad, N; Iyer, AKV; Kaushik, V; Way, LF; Yakisich, JS | 1 |
| Fuss, H; Jung, S; Lademann, J | 1 |
| Attanzio, A; Barraja, P; Carbone, A; Cascioferro, S; Cirrincione, G; Diana, P; Montalbano, A; Parrino, B; Spanò, V; Tesoriere, L; Ullo, S | 1 |
| Bi, X; Huang, D; Huang, W; Qian, H; Qiang, H; Shi, W | 1 |
| Biroccio, A; Ciriolo, MR; Del Bufalo, D; Di Leo, L; Iachettini, S; Leonetti, C; Lucidi, A; Mai, A; Rizzo, A; Rotili, D; Salvati, E; Steegborn, C; Trisciuoglio, D; Zizza, P | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Dybdal-Hargreaves, NF; Gangjee, A; Gentile, T; Hamel, E; Mooberry, SL; Pavana, RK; Risinger, AL; Shah, K | 1 |
| Wang, S; Wu, C; Wu, H; Ye, C; Zhao, J; Zhou, C; Zhu, C; Zou, D | 1 |
| Choi, YH; Jeon, MY; Kim, DE; Kim, S; Kim, SH; Kwon, TK; Lee, TJ; Min, KJ; Park, JW; Seo, SU; Woo, SM | 1 |
| Dickinson, NJ; Harper, J; Howard, P; Mao, S; Masterson, L; Pechenov, S; RiosDoria, J; Subramony, JA; Tyagi, P; Wetzel, L; Yo, K | 1 |
| Arkenau, HT; Bendell, JC; Chua, CC; Dukart, G; Harrow, K; Liang, C; Moore, KN; Patel, MR | 1 |
| Dong, X; Huang, X; Shao, J; Sun, L; Tang, Y; Wu, C; Xiao, W | 1 |
| Click, B; Regueiro, M | 1 |
| Cil, O; Duan, T; Thiagarajah, JR; Verkman, AS | 1 |
| Alewine, C; Antignani, A; FitzGerald, D; Gadina, M; Hewitt, SM; Simon, N | 1 |
| Chen, CH; Liou, JP; Liu, YM; Yeh, TK | 1 |
| Bender, S; Boemer, U; Collin, MP; Ellinghaus, P; Grünewald, S; Héroult, M; Hess-Stumpp, H; Ince, S; Kneip, C; Kopitz, C; Lustig, K; Mumberg, D; Politz, O; Thuss, U; Ziegelbauer, K; Zopf, D | 1 |
| Chen, TW; Cheng, AL; Chiu, LL; Hsu, CH; Ishizuka, T; Lee, JH; Lin, CC; Oguma, T; Sasaki, SI; Sugihara, M; Tajima, N; Yang, JC; Yen, YH | 1 |
| Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ | 1 |
| Cao, S; Du, R; Gao, R; Li, X; Wang, J; Wang, P; Wu, W; Xiang, R; Zhang, C; Zhu, H | 1 |
| Bedford, E; Bedford, MT; Gao, G; He, W; Moh, P; Shen, J; Shi, X; Su, D; Villarreal, OD; Xu, H; Zhang, L | 1 |
| Fujimura, S; Hirata, M; Kanai, Y; Ohmomo, Y; Sato, T; Temma, T; Yao, T; Yoshimoto, M | 1 |
| Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J | 1 |
| Fujita, N; Hashimoto, A; Kazuno, H; Komiya, Y; Kumazaki, M; Mizutani, T; Muraoka, H; Nakagawa, F; Ochiiwa, H; Ohkubo, S; Suzuki, S; Takenaka, T; Tsuji, S; Yoshimura, C | 1 |
| Adewole, KE; Ishola, AA | 1 |
| Duan, W; Luo, C; Shao, J; Tao, H; Yan, X; Zhang, H; Zhu, K | 1 |
| Funakoshi, T; Galsky, MD; Latif, A | 1 |
| Barraja, P; Carbone, A; Cirrincione, G; Diana, P; Fiebig, HH; Kelter, G; Maier, A; Parrino, B; Spanò, V | 1 |
| Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX | 1 |
| Hu, Y; Wu, P; Zhang, J | 1 |
| Chen, H; Guo, Q; Guo, Z; Shen, Z; Yang, Y; Zhou, Z | 1 |
| Arcari, JT; Beebe, JS; Berliner, MA; Bernardo, V; Boehm, M; Borzillo, GV; Chen, JM; Clark, T; Cohen, BD; Connell, RD; Frost, HN; Gordon, DA; Hungerford, WM; Kakar, SM; Kanter, A; Keene, NF; Knauth, EA; Lagreca, SD; Lu, Y; Martinez-Alsina, L; Marx, MA; Morris, J; Patel, NC; Savage, D; Soderstrom, CI; Thompson, C; Tkalcevic, G; Tom, NJ; Vajdos, FF; Valentine, JJ; Vincent, PW; Wessel, MD | 1 |
| Deodhar, A | 1 |
| Chen, D; Murugesan, S; Nadkarni, DH; Qin, JJ; Velu, SE; Wang, H; Wang, MH; Wang, W; Zhang, R | 1 |
| Prado, CM | 1 |
| Bitzer, M; Horger, M; Ioanoviciu, SD; Kopp, HG; Schulze, M; Spira, D; Wiesinger, B | 1 |
| Cheng, L; Li, Y; Li, Z; Liang, C; Liu, Y; Liu, Z; Wang, C; Xu, H; Yang, G | 1 |
| Blackwood, E; Cain, G; Choi, J; Epler, J; Evangelista, M; Flagella, M; Gazzard, L; Halladay, J; Jackson, PK; Jakubiak, D; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Schmidt, S; Williams, K; Wong, K; Xiao, Y; Yee, S; Yen, I | 1 |
| Chen, K; Li, JR; Li, X; Zhu, HL | 1 |
| Ellegaard, AM; Groth-Pedersen, L; Jäättelä, M; Kirkegaard, T; Klumperman, J; Nylandsted, J; Oorschot, V | 1 |
| Billard, C | 1 |
| Kamaike, K; Kashiwagi, K; Kawashima, E; Nakanishi, Y; Ohba, Y; Terui, Y; Tomitori, H | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Chang, C; Chen, X; Jiang, H; Lou, D; Qin, Q; Wang, J; Zhang, W; Zhong, D; Zhou, A | 1 |
| Bernabe, LF; Kisseberth, WC; London, CA; Nguyen, S; Pennell, M; Portela, R; Yancey, MF | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Bartholomew, P; Elwell, M; Radi, Z; Vogel, WM | 1 |
| de Wit, D; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; Hessing, T; König-Quartel, JM; Sparreboom, A; van Erp, NP | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Aghebati-Maleki, L; Baradaran, B; Shahneh, FZ; Zamani, F | 1 |
| Han, Y; Teng, B; Tian, Q; Wang, Q; Yang, S; Yao, KX; Zhang, J | 1 |
| Beijnen, JH; Huitema, AD; Knapen, LM; Lankheet, NA; Schellens, JH; Steeghs, N | 1 |
| Waldmann, TA | 1 |
| Kasak, L; Kauts, ML; Loog, M; Neuman, T; Piirsoo, A; Piirsoo, M; Tints, K; Uusen, P | 1 |
| Aboulafia, D; Cianfrocca, ME; Deeken, JF; Dezube, BJ; Dowlati, A; Gerecitano, J; Haigentz, M; Henry, DH; Ivy, SP; Little, RF; Mitsuyasu, RT; Moore, PC; Ratner, L; Rudek, MA; Sullivan, R | 1 |
| Chen, H; Hou, W; Rojas, J; Sampath, P; Thorne, SH | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Faivre, S; Ishak, KJ; Korytowsky, B; Proskorovsky, I; Sandin, R; Valle, J | 1 |
| Devasahayam, N; Krishna, MC; Lizak, MJ; Matsumoto, S; Matsuo, M; Merkle, H; Mitchell, JB; Morris, HD; Munasinghe, JP; Saito, K; Suburamanian, S; Takakusagi, Y; Yasukawa, K | 1 |
| Cho, Y; Jeon, S; Kim, YH; Lee, ES; Moon, JM | 1 |
| Guo, C; Li, J; Lin, M; Liu, K; Wang, L; Xu, T; Yang, B; Zhang, H; Zhang, X; Zhou, D | 1 |
| de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO | 1 |
| Kurzman, ID; Pan, X; Tsimbas, K; Vail, DM | 1 |
| Beijnen, JH; Cirkel, GA; de Jonge, MJ; Gadellaa-van Hooijdonk, CG; Haanen, JB; Huitema, AD; Kloth, JS; Lankheet, NA; Lolkema, MP; Mathijssen, RH; Schellens, JH; Sleijfer, S; Steeghs, N; Voest, EE | 1 |
| Dai, Z; Jin, Y; Li, Y; Ma, X; Shi, L; Tian, J; Zha, Z | 1 |
| Heng, DY; Imbulgoda, A; Kollmannsberger, C | 1 |
| Chai, H; Deng, Y; Keller, WJ; Kinghorn, AD; Li, J; Naman, CB; Pan, L | 1 |
| Borden, EC; Chen, H; Dowlati, A; Elson, P; Koon, H; Mittal, K; Rini, BI; Triozzi, P | 1 |
| Breazna, A; Demetri, GD; Ewer, MS; Lenihan, DJ; Motzer, RJ; Niculescu, L; Suter, TM | 1 |
| Abe, S; Higaki, K; Kimura, T; Ogawara, K; Un, K; Yoshizawa, Y | 1 |
| Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
| Alfonsi, R; Bai, R; Bolognesi, A; Brancale, A; Coluccia, A; Di Marcotullio, L; Dondio, G; Famiglini, V; Gulino, A; Hamel, E; La Regina, G; Lavia, P; Mazzoccoli, C; Mercurio, C; Miele, A; Nalli, M; Novellino, E; Passacantilli, S; Pelliccia, S; Rensen, WM; Ruggieri, V; Silvestri, R; Sisinni, L; Varasi, M; Vultaggio, S | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Rameshthangam, P; Srinivasan, P; Sudha, A | 1 |
| London, CA | 1 |
| Cho, Y; Hong, WY; Jeon, SH; Lee, ES | 1 |
| Chen, JX; Chen, WH; Dong, C; Lin, YL; Sun, B; Wang, B; Yang, JW; Zhou, CQ; Zhou, ZZ | 1 |
| Arrowood, CA; Honeycutt, W; Howard, L; Hurwitz, HI; Latta, K; Meadows, KL; Niedzwiecki, D; Rushing, C | 1 |
| Alexandre, J; Behouche, A; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Huillard, O; Loriot, MA; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
| Attwood, K; Burns, P; Cruz-Munoz, WR; Ebos, JM; Hudson, JM; Jedeszko, C; Kerbel, RS; Lee, CR; Mastri, M; Tracz, A | 1 |
| Biziato, D; De Palma, M | 1 |
| Alwan, WS; Bangalore, PK; Karpoormath, R; Naphade, SS; Palkar, MB; Patel, HM; Rane, RA; Shaikh, MS | 1 |
| Campbell, KH; Henderson, CJ; MacLeod, AK; McLaughlin, LA; McMahon, M; Wolf, CR | 1 |
| Borad, MJ; Bowles, DW; Calvo, E; Curtis, KK; Eckhardt, SG; Faessel, H; Gangolli, E; Goldman, J; Hidalgo, M; Parikh, A; Partyka, J; Rosen, LS; Ryan, DP; Stewart, S; Wirth, LJ | 1 |
| Lee, M; Patil, PC; Satam, V | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| Binkhorst, L; Burger, H; Chaves, I; de Bruijn, P; de Wit, AS; Hamberg, P; Kloth, JS; Lam, MH; Mathijssen, RH; van der Horst, GT; Wiemer, EA | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Kamal, A; Nekkanti, S; Sathish, M; Shankaraiah, N; Sreekanth, K; Srinivasulu, V | 1 |
| Belal, A | 1 |
| Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ | 1 |
| Iqbal, Y; Malik, MF; Riaz, SK | 1 |
| Awuah, SG; Bio, M; Cantu, R; D'Souza, F; Das, SK; Gobeze, HB; Nesterov, VN; Watley, RL; You, Y | 1 |
| Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
| Attanzio, A; Barraja, P; Carbone, A; Ciancimino, C; Cirrincione, G; Di Vita, G; Diana, P; Livrea, MA; Montalbano, A; Parrino, B; Spanò, V; Tesoriere, L | 1 |
| Benda, B; Curtis, JR; Geier, J; Kaplan, IV; Kwok, K; Lee, EB; Riese, R; Soma, K; Wang, L | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Chen, HM; Chen, SH; Coakley, BA; Divino, C; Eisenstein, S; Ferris, R; Gildener-Leapman, N; Kao, J; Ko, EC; Ma, G; Mandeli, J; Ozao, J; Pan, PY; Schwartz, M; Sung, M; Wang, LH | 1 |
| Barnhart, TE; Cai, W; Chakravarty, R; Chen, F; Goel, S; Hernandez, R; Hong, H; Valdovinos, HF | 1 |
| Abonia, R; Acosta, P; Butassi, E; Insuasty, B; Ortiz, A; Quiroga, J; Zacchino, SA | 1 |
| Cherrington, JM; Laird, AD; Mendel, DB | 1 |
| Abonante, S; Cafeo, G; De Francesco, EM; De Marco, P; Dolce, V; Felli, L; Kohnke, FH; Lappano, R; Maggiolini, M; Pisano, A; Ponassi, M; Rosano, C; Santolla, MF | 1 |
| Baldetorp, B; Döme, B; Fehniger, TE; Gustavsson, L; Kim, Y; Kwon, HJ; Malm, J; Marko-Varga, G; Nishimura, T; Sugihara, Y; Török, S; Végvári, Á; Watanabe, K; Welinder, C | 1 |
| Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ | 1 |
| Kleibeuker, EA; Slotman, BJ; Ten Hooven, MA; Thijssen, VL; Verheul, HM | 1 |
| Gemma, A; Miyanaga, A | 1 |
| Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
| Li, R | 1 |
| Crafter, C; D'Cruz, CM; Davies, BR; Dudley, P; Guan, N; Hanson, L; Jacobs, V; Jacques, K; James, N; Jenkins, EL; Kodaira, M; Ladd, B; Lindemann, J; Logie, A; Tamura, K; Zinda, M | 1 |
| Demko, N; Federico, CA; Fergusson, D; Hakala, A; Henderson, VC; Kimmelman, J; MacKinnon, N | 1 |
| Chen, S; Chen, X; Dong, B; Huang, Q; Li, A; Li, Q; Liu, Y; Miao, J; Wang, Z; Yao, M; Zhang, N; Zhou, C | 1 |
| Dervan, PB; Kang, JS | 1 |
| Carlisle, B; Demko, N; Freeman, G; Hakala, A; Hey, S; Kimmelman, J; London, AJ; MacKinnon, N; Ramsay, T | 1 |
| Gardner, EE; Rudin, CM | 1 |
| Brunelli, C; Carbone, F; Di Iorio, C; Gigli, L; Montecucco, F; Nencioni, A; Rosa, GM; Tagliasacchi, MI | 1 |
| Varvounis, G | 1 |
| Benedetto, P; Flores, A; Kovacs, K; Kwon, D; Merchan, JR; Montero, AJ; Rocha-Lima, C; Trent, JC | 1 |
| Gong, P; Luo, R; Tang, Q; Tu, Q; Tu, Y; Wang, L; Wang, P; Wu, C; Zheng, P; Zhu, W | 1 |
| Eckstein, N; Frötschl, R; Haas, B; Weber-Lassalle, K | 1 |
| Arita, S; Chen, L; Esaki, T; Hashimoto, J; Hirai, F; Kawata, T; Kodaira, M; Lindemann, J; Seto, T; Tamura, K; Tanabe, Y; Toyokawa, G; Yamamoto, H; Yonemori, K | 1 |
| Bergman, PJ; Merrick, CH; Pierro, J; Regan, RC; Schleis, SE; Siedlecki, CT; Sones, EA; Wright, ZM | 1 |
| Cai, Y; Dong, X; Huang, W; Si, W; Tang, Q; Wu, X; Zhang, Q | 1 |
| Devine, L; Kelly, WK; Kluger, H; Lee, JJ; Li, J; Rink, L; Saif, MW | 1 |
| Boison, D; Chen, QY; Gao, J; Lu, NN; Weng, ZY; Xiao, XX | 1 |
| Cannell, PK; Harrison, SJ; Mainwaring, P; Millward, MJ; Padrik, P; Price, T; Reich, SD; Spencer, A; Trikha, M; Underhill, CR | 1 |
| Biller, BJ; Kurzman, ID; Pellin, MA; Robinson, K; Tsimbas, K; Vail, DM; Wouda, RM | 1 |
| Markovic, LE; Stein, TJ; Stepien, RL; Tjostheim, SS | 1 |
| Baracos, VE; Bathe, OF; Cervo, L; Giavazzi, R; Lecker, SH; Martinelli, GB; Olivari, D; Ottoboni, L; Piccirillo, R; Re Cecconi, AD; Resovi, A; Stretch, C; Talamini, L | 1 |
| Kłoczko, J; Ołdziej, AE; Romaniuk, W; Zińczuk, J | 1 |
| Bawn, RH; Bisset, LC; Blackburn, TJ; Cano, C; Clegg, W; Cottyn, B; Golding, BT; Griffin, RJ; Hammonds, T; Hardcastle, IR; Harrington, RW; Leung, H; Molyneux, L; Myers, SM; Newell, DR; Rigoreau, L; Vidot, S; Wong, AC | 1 |
| Del Rosario, G; Dragovich, PS; Erickson, HK; He, J; Hop, CE; Khojasteh, SC; Liu, L; Ma, Y; Pei, Z; Pillow, TH; Sadowsky, JD; Xu, K; Yu, SF; Zhang, D | 1 |
| Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R | 1 |
| Flanagan, KJ; Gräfe, S; Gutsche, CS; Kulak, N; Ortwerth, M; Reissig, HU; Senge, MO; Wiehe, A | 1 |
| Abe, M; Andersson, P; Cao, R; Cao, Y; Chen, F; Chen, X; Fischer, C; Hosaka, K; Iwamoto, H; Lim, S; Lu, Y; Nakamura, M; Nie, G; Seki, T; Skov, PV; Yang, Y; Zhang, Y | 1 |
| Lan, L; Mao, ZM; Qi, Q; Wang, S; Wang, YL; Xin, YX; Zhan, XP; Zhao, K | 1 |
| Gibson, KR; Harrigan, JA; Jacq, X; Knights, C; McLellan, L; Stockley, M; Tate, EW; Ward, JA; Whitlock, GA | 1 |
| Benoit, G; Benoudiba, F; Brizard, M; Caillet, V; Corréas, JM; David, P; Deveaux, S; Elaidi, R; Gaudric, A; Hammel, P; Joly, D; Le Rest, C; Méjean, A; Oudard, S; Richard, S; Timsit, MO | 1 |
| Conrado, D; Cook, J; Dikranian, A; Dowty, ME; Furst, DE; Hutmacher, MM; Krishnaswami, S; Lamba, M; Nduaka, C; Stock, T | 1 |
| Cohen, SB; Sivaraman, P | 1 |
| Abdel-Aziz, AK; Bornaghi, V; Bossi, D; Colecchia, M; Elgendy, M; Fazio, N; Giandomenico, V; Kanesvaran, R; Lanfrancone, L; Lozano, MD; Mercurio, C; Minucci, S; Nole, F; Pallavicini, I; Perez-Gracia, JL; Procopio, G; Renne, G; Renne, SL; Teh, BT; Toh, CK | 1 |
| Wang, M; Wang, X; Xu, C; Xu, K; Yang, C | 1 |
| Atyabi, F; Bahrainian, S; Dinarvand, R; Saber, MM | 1 |
| Abd-El Hameed, RH; Fatahala, SS; Mohamed, MS; Youns, M | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Antón-Aparicio, LM; Leon, LA | 1 |
| Barraja, P; Carbone, A; Cascioferro, S; Cilibrasi, V; Cirrincione, G; Diana, P; Doria, F; Frasson, I; Freccero, M; Giallombardo, D; Montalbano, A; Parrino, B; Richter, SN; Salvador, A; Spanò, V | 1 |
| Chen, J; Del Rosario, G; Fang, F; Flygare, JA; Go, MAT; Gregson, SJ; Gunzner-Toste, J; He, J; Howard, PW; Junutula, JR; Kamath, AV; Kozak, KK; Lau, J; Leipold, DD; Liu, L; Masterson, L; Ng, C; Ohri, R; Pillow, TH; Polakis, P; Polson, AG; Poon, KA; Sadowsky, J; Schutten, M; Solis, W; Spencer, S; Xu, K; Yee, S; Yu, SF; Zhang, D; Zhong, F | 1 |
| Winthrop, KL | 1 |
| Bharathiraja, S; Manivasagan, P; Oh, J; Oh, YO; Quang Bui, N; Santha Moorthy, M; Seo, H; Song, K; Yoon, M | 1 |
| Brullo, C; Fallacara, AL; Grossi, G; Musumeci, F; Sanna, M; Schenone, S | 1 |
| Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Gomez-Reino, JJ; Maneiro, JR; Souto, A | 1 |
| Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B | 1 |
| Alves, F; Schmuck, K; Schuberth, I; Schuster, HJ; Tietze, LF | 1 |
| Xiao, H; Yang, CS | 1 |
| Del Conte, G; Guibal, A; Rüegg, C; Sessa, C | 1 |
| Abrams, MT; Breslin, MJ; Buser, CA; Coleman, PJ; Cox, CD; Davide, JP; Diehl, RE; Fernandez-Metzler, C; Fraley, ME; Garbaccio, RM; Hamilton, K; Hartman, GD; Huber, HE; Kohl, NE; Kuo, LC; Li, C; Lobell, RB; Mahan, E; Prueksaritanont, T; Schaber, MD; Slaughter, DE; South, VJ; Tao, W; Torrent, M; Walsh, ES; Whitman, DB; Yan, Y | 1 |
| Marzo, I; Naval, J | 1 |
| Azmi, AS; Mohammad, RM | 1 |
| Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S | 1 |
| Davis, P; Garfield, DH; Hercbergs, A; Schöffski, P; Wolter, P | 1 |
| Lenihan, DJ | 1 |
| Messori, A; Trippoli, S | 1 |
| Alves, F; Krewer, B; Major, F; Müller, M; Schuberth, I; Schuster, HJ; Tietze, LF; von Hof, JM | 1 |
| Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT | 1 |
| De Nanteuil, G; Gloanec, P; Golsteyn, RM; Hickman, J; Parmentier, JG; Pierré, A; Portevin, B | 1 |
| Sun, W; Wang, GS; Xu, LB; Xu, Y; Yang, XH | 1 |
| Sun, Y; Wang, C | 1 |
| Krewer, B; Schuberth, I; Schuster, HJ; Tietze, LF | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 3 |
| Awada, AH; Hatoum, HA; Ishak, RS; Otrock, ZK; Shamseddine, AI | 1 |
| Kang, MH; Reynolds, CP | 1 |
| Chen, ZS; Dai, CL; Fu, LW; Liang, YJ; Tiwari, AK; Tong, XZ; Wang, F; Wang, YS; Yan, YY | 1 |
| Bjarnason, GA; Christensen, JG; Cruz-Munoz, W; Ebos, JM; Kerbel, RS; Lee, CR | 1 |
| Amantea, M; Bello, CL; Houk, BE; Kang, D | 1 |
| Begent, RH; Clingen, PH; Cobb, M; Gumbrell, L; Hartley, JA; Hochhauser, D; Jodrell, D; Loadman, P; Meyer, T; Spanswick, VJ; Wu, J | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F | 1 |
| Benichou, AS; Billemont, B; Blanchet, B; Dauphin, A; Goldwasser, F; Ropert, S; Saboureau, C; Taieb, F; Tod, M | 1 |
| Maitland, ML; Snider, KL | 1 |
| Chen, MH | 1 |
| Tsukamoto, S; Yokosawa, H | 1 |
| Billemont, B; Kelly, RJ; Rixe, O | 1 |
| Gan, HK; Knox, JJ; Seruga, B | 1 |
| Shibuya, M | 1 |
| English, BC; Figg, WD; Price, DK | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Brower, V | 1 |
| Cortés-Funes, H | 1 |
| Cesaretti, JA; Chen, SH; Huang, D; Kao, J; Lo, YC; Packer, S; Schwartz, ME; Stock, RG; Sung, MW; Vu, HL | 1 |
| Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
| Letai, A; Ni Chonghaile, T | 1 |
| Krewer, B; Tietze, LF | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Ivy, SP; Kaufman, BM; Wick, JY | 1 |
| Beatty, K; Bokar, J; Borden, E; Budd, GT; Bukowski, RM; Chen, HX; Cooney, MM; Dolwati, A; Dreicer, R; Elson, P; Garcia, JA; Ivy, P; Mekhail, T; Rini, BI; Triozzi, P; Tyler, A | 1 |
| Grover, RK; Rao, PN | 1 |
| Papaetis, GS; Syrigos, KN | 1 |
| Baum, C; Bello, CL; Dinolfo, M; Huang, X; Levine, S; Mulay, M; Patyna, S; Rosen, L; Toh, M; Van Vugt, A | 1 |
| Bello, CL; Demetri, GD; Houk, BE; Motzer, RJ; Poland, B; Rosen, LS | 1 |
| Gu, Y; Meng, F; Qu, B; Shu, Y; Sun, Y; Xu, Q; Zhao, W; Zhu, X | 1 |
| Butler, S; Campiani, G; Fayne, D; Lawler, M; Lloyd, DG; McGovern, NN; Meegan, MJ; Nathwani, SM; Sarkadi, B; Williams, DC; Zisterer, DM | 1 |
| Wang, ZY | 1 |
| Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
| Chao, R; Harper, K; Huang, X; Ilagan, J; Liu, G; Robert, F; Sandler, A; Schiller, JH; Traynor, AM; Tye, L; Verkh, L | 1 |
| De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
| Fan, J; Ge, F; Liao, XJ; Liu, QY; Pang, HD; Xiong, S; Xu, SH; Yang, XX | 1 |
| Heng, DY; Kollmannsberger, C | 1 |
| Bando, T; Kashiwazaki, G; Minoshima, M; Nishijima, S; Shinohara, K; Sugiyama, H | 1 |
| Canipari, C; De Amici, M; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L | 1 |
| Minor, DR | 1 |
| Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA | 1 |
| Chen, SH; Eisenstein, S; Fu, S; Kao, J; Ko, EC; Sikora, AG | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Devarajan, P | 1 |
| Figulla, HR; Hannig, M; Sauer, H; Wartenberg, M | 1 |
| Bertolotti, M; Bosotti, R; Brasca, MG; Calogero, R; Ciomei, M; De Baere, T; Fiorentini, F; Galvani, A; Isacchi, A; Lazar, V; Locatelli, G; Mercurio, C; Pesenti, E; Scaburri, A; Scacheri, E; Soria, JC | 1 |
| Bergqvist, S; Christensen, JG; Dagostino, E; Guo, C; Karlicek, S; Kephart, SE; Knighton, D; Kraynov, E; Lamerdin, J; Loi, CM; Marakovits, J; Martinez, R; Murray, BW; Piraino, J; Popoff, I; Smeal, T; Westwick, JK; Zager, M; Zhang, C | 1 |
| Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R | 1 |
| Kelleher, FC; McDermott, R | 1 |
| Pérez-Tomás, R; Viñas, M | 1 |
| Lam, KS; Potts, BC | 1 |
| Airoldi, M; Barone, C; Caponigro, F; Comis, S; Crippa, S; Fiorentini, F; Fornari, G; Jannuzzo, MG; Lorusso, D; MacArthur, R; Merlano, M; Petroccione, A; Schena, M; Weitman, S | 1 |
| Ashwell, MA; Chen, CR; France, DS; Hill, J; Jeay, S; Leggett, DS; Li, CJ; Li, Y; Moussa, MM; Munshi, N | 1 |
| den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J | 1 |
| Baker, SD; Chen, Z; den Hartigh, J; den Hollander, M; Gelderblom, H; Guchelaar, HJ; König-Quartel, JM; Ploeger, BA; van Erp, NP; Zandvliet, AS | 1 |
| Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
| Saijo, N | 1 |
| Sato, Y | 1 |
| Berger, MS; Deeken, JF; Hwang, JJ; Kuruvilla, J; Marshall, JL; Mendelson, D; Pishvaian, MJ; Siu, LL; Viallet, J | 1 |
| Brandes, AA; Franceschi, E; Girardi, F | 1 |
| Billaud, M; Viollet, B | 1 |
| Cho, CH; Kim, TY; Park, JW; Shin, HW | 1 |
| Chang, MH; Cherian, C; Desmoulin, SK; Fulterer, A; Gangjee, A; Hou, Z; Matherly, LH; Romero, MF; Stout, M; Wang, Y; Wu, J | 1 |
| Eames, T; Staehler, M; Wollenberg, A | 1 |
| Bouattour, M; Colichi, C; Delbaldo, C; Dreyer, C; Faivre, S; Raymond, E; Sablin, MP | 1 |
| Chen, Z; Coffils, M; Fegan, C; Gregson, SJ; Hamaguchi, A; Hartley, JA; Hartley, JM; Howard, PW; Lin, TT; Martin, CR; Masterson, LA; Pepper, C; Suggitt, M; Thurston, DE; Tiberghien, AC | 1 |
| Fischer, BS; Gan, J; Ganapathi, R; Gong, J; Iyer, R; Masson, E; Mekhail, T; Patricia, D; Pursley, J; Williams, D | 1 |
| Camacho, JR; Martínez, R; Osornio, YM; Ramírez-Apan, MT; Reyes-Gutiérrez, PE | 1 |
| Vollmar, AM; von Schwarzenberg, K | 1 |
| Arioka, H; Murakami, H; Shimoyama, T; Tamura, T; Ueda, Y; Yamada, Y; Yamamoto, N | 2 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Al-Tel, TH | 1 |
| Ezell, SJ; Gurpinar, E; Li, H; Rayburn, ER; Sommers, CI; Velu, SE; Wang, W; Xu, H; Yang, X; Zhang, R; Zhang, X | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Andrews, DW; Geng, F; Kale, J; Leber, B | 1 |
| Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF | 1 |
| Gulder, TA; Moore, BS | 1 |
| Ardini, E; Galvani, A; Magnaghi, P; Menichincheri, M; Orsini, P | 1 |
| Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J | 1 |
| Schmidt, C | 1 |
| Chacko, AD; Crawford, N; Fennell, DA; Longley, DB; McCoy, F; Redmond, K; Savage, KI | 1 |
| Dempke, WC; Zippel, R | 1 |
| Bertolini, F; Braidotti, P; Calleri, A; Mancuso, P; Marighetti, P; Martin-Padura, I; Quarna, J; Rabascio, C | 1 |
| Villabona, C | 1 |
| Campiani, G; Forde, JC; Hollywood, D; Lawler, M; Lynch, TH; Maginn, EN; Marignol, L; Martin, LM; McElligott, AM; McNamara, G; Williams, DC; Zisterer, D | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Chu, DT | 1 |
| Aono, Y; Nishioka, Y; Sone, S | 1 |
| Chen, P; Fink, BE; Gavai, AV; Goyal, B; Kim, SH; Lee, FY; Mastalerz, H; Norris, D; Oppenheimer, S; Tokarski, JS; Vite, GD; Wong, TW; Zhang, H; Zhao, Y | 1 |
| Aherne, W; Caldwell, JJ; Collins, I; de Haven Brandon, A; Eccles, SA; Eve, PD; Garrett, MD; Heaton, SP; Henley, A; Hunter, LJ; Pickard, L; Raynaud, FI; Ruddle, R; Thompson, NT; Valenti, M; Vijayaraghavan, G; Walton, MI; Workman, P; Yap, TA | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Bahleda, R; Chaput, N; Conforti, R; Flament, C; Gdoura, A; Kroemer, G; Litvinova, E; Soria, JC; Soumelis, V; Viaud, S; Zitvogel, L; Zoubir, M | 1 |
| Cox, CD; Garbaccio, RM | 1 |
| Greten, TF; Korangy, F; Manns, MP | 1 |
| Albitar, MX; Anderson, KC; Baritaki, S; Berkers, C; Bonavida, B; Chandra, J; Chauhan, D; Cusack, JC; Fenical, W; Ghobrial, IM; Groll, M; Jensen, PR; Lam, KS; Lloyd, GK; McBride, W; McConkey, DJ; Miller, CP; Neuteboom, ST; Oki, Y; Ovaa, H; Pajonk, F; Palladino, MA; Potts, BC; Richardson, PG; Roccaro, AM; Sloss, CM; Spear, MA; Valashi, E; Younes, A | 1 |
| Berlin, JD; Calcutt, MW; Chen, AP; Hachey, DL; Hartley, JA; Lee, W; Liao, CY; Puzanov, I; Rothenberg, ML; Spanswick, VJ; Vermeulen, WL | 1 |
| Anthoney, DA; Armand, JP; Balheda, R; Kroemer, G; Laffranchi, B; Massard, C; Pacciarini, MA; Pellizzoni, C; Proctor, A; Scaburri, A; Soria, JC; Twelves, CJ | 1 |
| Diaz-Padilla, I; Siu, LL | 1 |
| Agrawal, N; Chen, C; DiPaola, R; Holen, K; Hsu, K; Liu, G; Rosenberg, E; Stein, M; Tan, AR; Wilding, G; Xue, L | 1 |
| Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K | 1 |
| Emanuel, S; Fairchild, C; Fargnoli, J; Fink, B; Gavai, A; Hammell, A; Henley, B; Hilt, C; Hunt, JT; Krishnan, B; Kukral, D; Lee, FY; Lewin, A; Malone, H; Norris, D; Oppenheimer, S; Vite, G; Wong, TW; Yu, C | 1 |
| Geoerger, B; Leblond, P | 1 |
| Kay, LE; Ruschak, AM; Schimmer, AD; Slassi, M | 1 |
| Chang, TT; Chen, TJ; Hsu, JC; Jen, YC; Li, WS; Lu, CK; Lu, IH; More, SV | 1 |
| Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; Dubois, SG; Glade-Bender, J; Grier, HE; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S; Wu, B | 1 |
| Bag, I; Juvekar, A; Kamal, A; Kumar, GB; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, MK; Reddy, VS; Sen, S; Srikanth, YV; Zingde, SM | 1 |
| Choi, Y; Kim, DE; Lee, DK; Park, JE; Schellingerhout, D; Shon, SM | 1 |
| Li, Z; Lin, S; Wang, X; Wei, Y; Yang, H; Zhao, C; Zhao, Y | 1 |
| Clark, BR; Fox, D; Leroy, J; Murphy, CD; O'Connor, S | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Hollyfield, JG; Hong, L; Salomon, RG | 1 |
| Assaraf, YG; Beerepoot, LV; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Griffioen, AW; Honeywell, RJ; Jansen, G; Labots, M; Musters, RJ; Peters, GJ; Pili, R; Rudek, MA; Verheul, HM | 1 |
| Bjørkøy, G; Fuglseth, E; Hoff, BH; Kaspersen, SJ; Kjøbli, E; Sundby, E; Sørum, C; Willassen, V | 1 |
| Carmichael, L; Chao, B; Eickhoff, J; Harrison, M; Ivy, P; Jeraj, R; Kolesar, J; Liu, G; Marnocha, R; Perlman, S; Simoncic, U; Vanderhoek, M; Wilding, G | 1 |
| Aparicio, LM; Gallego, GA; Pulido, EG | 1 |
| Amiri-Kordestani, L; Bates, SE; Fojo, T | 1 |
| Ghalali, A; Högberg, J; Stenius, U; Ye, ZW | 1 |
| Reed, MW; Young, RJ | 1 |
| Armes, SP; Au, KM; Lu, Z; Matcher, SJ | 1 |
| Adamson, PC; Ahern, CH; Baruchel, S; Blaney, SM; DuBois, SG; Glade-Bender, J; Ingle, AM; Ivy, P; Reid, JM; Shusterman, S | 1 |
| Chon, E; Kubicek, LN; McCartan, L; Vail, DM | 1 |
| Alvarez, F; Beaver, L; Bryan, J; Carreras, J; Clifford, C; Ettinger, S; Fulton, L; Gauthier, M; Gill, V; Gillings, S; Haney, S; Henry, C; Hershey, B; Higginbotham, ML; Hillman, L; Jones, P; Kiselow, M; Klein, MK; Krick, E; Ladue, T; London, C; Mathie, T; McNeill, C; Novasad, A; Phillips, B; Stingle, N; Thamm, D; Vail, DM; Vaughan, A; Vickery, K | 1 |
| Deeken, JF; He, P; Rais, R; Rudek, MA; Xu, L; Zhao, M | 1 |
| Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
| Bareford, MD; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Poklepovic, A | 1 |
| Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N | 1 |
| Döme, B; Török, S | 1 |
| Basaga, H; Bodur, C | 1 |
| Conley, SJ; Wicha, MS | 1 |
| Telli, M; Witteles, RM | 1 |
| Hartley, JA; Hochhauser, D | 1 |
| Budha, N; Buonarati, MH; Dean, B; Hop, CE; Jones, SA; Murakami, SC; Shin, YG; Ware, J; Wong, H | 1 |
| Camidge, DR; Chan, E; Chow Maneval, E; Diab, S; Eckhardt, SG; Khosravan, R; Leong, S; Lin, X; Lockhart, AC; Messersmith, WA; Spratlin, J | 1 |
| Davids, MS; Letai, A | 1 |
| Cesaretti, JA; Chen, SH; Forsythe, K; Galsky, M; Genden, EM; Kao, J; Ko, EC; Lau, KH; Ozao-Choy, J; Packer, SH; Schwartz, M; Stock, RG; Sung, MW; Tong, CC | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Yang, HY | 1 |
| Davies, TG; de Haven Brandon, AK; Eccles, SA; Eve, PD; Feltell, RE; Garrett, MD; Grimshaw, KM; Heaton, SP; Heinzmann, K; Jones, PS; Lyons, JF; Martins, V; Raynaud, FI; Reule, M; Te Poele, RH; Thompson, NT; Valenti, MR; Walton, MI; Woodhead, SJ; Workman, P; Yap, TA; Zetterlund, A | 1 |
| Chang, X; Liu, Y; Shen, X; Song, T; Zhang, Z | 1 |
| Chen, M; Fang, X; Tang, S; Zheng, N | 1 |
| Airley, R | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P | 1 |
| Goto, Y; Hirata, T; Ikeda, Y; Nokihara, H; Tamura, T; Tanioka, M; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Argyle, DJ; Bavcar, S | 1 |
| Cheng, L; Liu, Z; Sun, C; Wang, J; Xu, H; Yang, K | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Bottai, G; Santarpia, L | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Bradley, JM; Cohen, PA; Dominguez, AL; Finke, JH; Gendler, SJ; Gorman, JE; Ko, JS; McCurry, DB; Pathangey, LB; Rayman, PA; Rini, BI; Spencer, CD; Storkus, WJ; Zorro-Manrique, S | 1 |
| Chen, X; Diao, X; Gao, Z; Guo, Z; Jiang, H; Xie, C; Zhang, L; Zhong, D; Zhou, J | 1 |
| Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP | 1 |
| Chang, X; Feng, Y; Li, X; Liang, X; Song, T; Su, P; Wu, G; Wu, Z; Xie, S; Zhang, Z; Zhao, Y | 1 |
| Funakoshi, T; Shimada, YJ | 1 |
| Asahi, S; Kogame, A; Kondo, T; Miyamoto, M; Prakash, S; Shibata, S; Shyu, WC; Tagawa, Y; Tohyama, K; Tojo, H | 1 |
| Akintayo, A; Chen, Z; El-Rayes, B; Fanucchi, MP; Harvey, RD; Kauh, JS; Khuri, FR; Lewis, CM; Nadella, P; Owonikoko, TK; Ramalingam, SS; Rogatko, A; Shin, DM; Tighiouart, M | 1 |
| Rose, S | 1 |
| Cropp, G; Gosalia, R; Hannah, A; Sheldon, M; Stopeck, A; Vahedian, M | 1 |
| Garber, K | 2 |
| Curran, WJ | 1 |
| Rosen, LS | 1 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Alileche, A | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Traxler, P | 1 |
| Kumar, R; Lown, JW | 1 |
| Ravnskov, U | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Boucher, J; Cherrington, JM; Chien, MB; Downing, S; Hannah, AL; Kollias-Baker, C; London, CA; McMahon, G; Mendel, DB; Post, G; Rosenberg, M; Shenoy, N; Zadovoskaya, R | 1 |
| Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J | 1 |
| Antonellini, A; De Jonge, MJ; Fiorentini, F; Fowst, C; Hartman, CM; Mantel, M; Planting, AS; Sparreboom, A; Stoter, G; Ten Tije, AJ; Tursi, J; Van Der Gaast, A; Verweij, J | 1 |
| Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN | 1 |
| Kuenen, BC | 1 |
| CAMPBELL, GW; DULANEY, EL; GITTERMAN, CO; HENDLIN, D; KACZKA, EA; WOODRUFF, HB | 1 |
| MCAFEE, J; RUBENFELD, S; WINKELMAN, J | 1 |
| MARKLE, V; PAZDER, LH; TAYLOR, JD | 1 |
| Blake, RA; Chan, J; Harris, D; Howlett, AR; Kiewlich, D; Le, P; Liang, C; Lipson, KE; McMahon, G; Miller, T; Patel, N; Rice, A; Sun, L; Vasile, S; Wang, X | 1 |
| Shiotsu, Y | 1 |
| Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P | 1 |
| Abdollahi, A; Bischof, M; Debus, J; Grone, HJ; Hahnfeldt, P; Han, X; Hlatky, L; Huber, PE; Klenke, F; Krix, M; Lipson, KE; Poerschke, D; Roth, A; Sckell, A; Zieher, H | 1 |
| Berlin, JD; Campbell, A; Fiorentini, F; Fontana, E; Fowst, C; Hande, KR; Howard, M; Lankford, O; Lockhart, AC; Paty, VA; Roth, BJ; Rothenberg, ML; Vreeland, F | 1 |
| Bando, T; Iwai, A; Kihara, K; Narita, A; Sugiyama, H | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; García-Echeverría, C; Hideshima, T; Hofmann, F; Joseph, M; Kung, AL; Libermann, TA; McMullan, CJ; Mitsiades, CS; Mitsiades, NS; Pearson, MA; Poulaki, V; Shringarpure, R | 1 |
| Broggini, M; Fontana, E; Fowst, C; Geroni, C; Marchini, S; Moneta, D | 1 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
| Dellian, M; Eichhorn, ME; Strieth, S | 1 |
| Bailly, C | 1 |
| Abbruzzese, JL; Charnsangavej, CA; Davis, D; Faria, SC; Herbst, R; Hess, K; Hicks, M; Jackson, EF; Madden, T; McConkey, D; Scholz, C; Xiong, HQ | 1 |
| Abdollahi, A; Bischof, M; Debus, JU; Gong, P; Huber, PE; Lipson, KE; Stoffregen, C; Weber, KJ | 1 |
| Bajgar, R; Huf, M; Kolárová, H; Macecek, J; Mosinger, J; Nevrelová, P; Strnad, M; Tomecka, M; Tomek, P | 1 |
| Atteridge, CE; Biggs, WH; Carter, TA; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Grotzfeld, RM; Herrgard, S; Insko, DE; Lockhart, DJ; Mehta, SA; Milanov, ZV; Pao, W; Patel, HK; Sawyers, CL; Shah, NP; Treiber, DK; Varmus, H; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Rabindran, SK | 1 |
| Giaccone, G; Hoekman, K; Kok, A; Kuenen, BC; Pinedo, HM; Ruijter, R; Schalkwijk, C | 1 |
| Bucana, C; de Heus, G; Dumez, H; Eskens, FA; Fidler, IJ; Hoekstra, R; Planting, AS; Ravera, C; Sizer, KC; Vaidyanathan, S; van der Gaast, A; van Oosterom, AT; Verweij, J | 1 |
| Aherne, W; Hannah, A; Hardcastle, A; Hayes, C; Judson, I; Kakkar, AJ; Leach, M; O'Donnell, A; Padhani, A; Phillips, S; Raynaud, F; Scurr, M; Trigo, JM; Workman, P | 1 |
| Ambrus, K; Herrmann, R; Pless, M; Rochlitz, C; Salzberg, M; Scigalla, P | 1 |
| Shore, GC; Viallet, J | 1 |
| Stadler, WM | 1 |
| Armand, JP; Bello, C; Brega, N; Delbaldo, C; Deprimo, S; Faivre, S; Lassau, N; Lozahic, S; Massimini, G; Raymond, E; Robert, C; Scigalla, P; Vera, K | 1 |
| Veryard, C | 1 |
| Fu, A; Hallahan, DE; Huamani, J; Kim, DW | 1 |
| Gianni, L; Grasselli, G; Ielmini, N; Lladò, A; Locatelli, A; Marimon, I; Marsoni, S; Sessa, C; Trigo, J; Viganò, L | 1 |
| Bando, T; Minoshima, M; Sakakibara, Y; Sasaki, S; Shinohara, K; Sugiyama, H | 1 |
| Bello, CL; Christensen, JG; Hoosen, S; Motzer, RJ | 1 |
| Gasparini, G; Longo, R; Sarmiento, R | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Major, F; Schuberth, I; Tietze, LF | 1 |
| Bando, T; Minoshima, M; Sasaki, S; Shimizu, T; Shinohara, K; Sugiyama, H; Takaoka, T | 1 |
| Curtiss, FR | 1 |
| Bernasconi, P; Calatroni, S; Crosetto, N; Dikic, I | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Bae, Y; Fujii, T; Hirakawa, K; Iwata, C; Kaminishi, M; Kano, MR; Kataoka, K; Kiyono, K; Komuro, A; Miyazono, K; Morishita, Y; Nishiyama, N; Oka, M; Ouchi, Y; Yashiro, M | 1 |
| Chow, LQ; Eckhardt, SG | 1 |
| Heldin, CH; Ostman, A | 1 |
| Force, T; Krause, DS; Van Etten, RA | 1 |
| Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A | 1 |
| Senan, S; Smit, EF | 1 |
| Blay, JY | 1 |
| Baum, C; Bello, CL; Britten, CD; Hecht, JR; Kabbinavar, F; Li, J; Slamon, D | 1 |
| Kamba, T; McDonald, DM | 1 |
| Di Lorenzo, L | 1 |
| Chang, M; Chen, P; Fink, BE; Gavai, A; Han, WC; Johnson, W; Langley, D; Leavitt, K; Lee, FY; Marathe, P; Mastalerz, H; Norris, D; Oppenheimer, S; Sleczka, B; Tarrant, J; Tokarski, JS; Vite, GD; Vyas, DM; Wong, H; Wong, TW; Zhang, G; Zhang, H | 1 |
| Kibble, A; Shumoogam, J | 1 |
| Demetri, G; Faivre, S; Raymond, E; Sargent, W | 1 |
| George, D; Verweij, J | 1 |
| Bello, C; DePrimo, SE | 1 |
| Christensen, JG | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Rini, BI | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Christensen, JG; Ebos, JM; Kerbel, RS; Lee, CR; Mutsaers, AJ | 1 |
| Davis, P; Garfield, D; Hercbergs, A | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Campiani, G; Greene, LM; Lawler, M; Williams, DC; Zisterer, DM | 1 |
| Auperin, A; Bourhis, J; Deutsch, E; Frascogna, V; Lecluse, Y; Tao, Y; Zhang, P | 1 |
| Han, EK; McGonigal, T | 1 |
| Joensuu, H | 1 |
| Andraos, R; Cheong, R; Feinberg, AP; Iacobuzio-Donahue, CA; Kaneda, A; Ko, MS; Levchenko, A; Longo, DL; Ohlsson, R; Onyango, P; Pearson, MA; Sharov, AA; Timp, W; Wang, CJ; Wen, B | 1 |
| Devaiah, V; Juvekar, A; Kamal, A; Kurian, N; Laxma Reddy, K; Sen, S; Shankaraiah, N; Zingde, S | 1 |
| Goldstein, MR | 1 |
| Giordano, S; Petrelli, A | 1 |
| Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H | 1 |
| Bickford, C; Champion, JC; Durand, JB; Halushka, M; Kassiotis, CM; Khakoo, AY; Lenihan, DJ; Plana, JC; Tannir, N; Trent, J | 1 |
| Baritaki, S; Berenson, J; Bonavida, B; Daniels, TR; Jazirehi, AR; Palladino, M; Penichet, ML; Spandidos, DA; Suzuki, E; Umezawa, K | 1 |
| Kapoor, S | 1 |
| Anderson, WK | 1 |
| Newmark, HL | 2 |
| Heidrich, G; Houde, RW; Kaiko, RF; Rogers, A; Wallenstein, SL | 1 |
| Stambaugh, JE; Tejada, F; Trudnowski, RJ | 1 |
| Judd, KP; Reif, AE; Southwick, PL | 1 |
| Gust, D; Jori, G; Moore, AL; Moore, TA; Reddi, E | 1 |
| Becker, M; Buchdunger, E; Cozens, RM; Daniels, D; Lydon, NB; Mett, H; Mueller, M; Stover, D; Traxler, P | 1 |
| Stephenson, J | 1 |
| Kuwano, M; Ono, M | 1 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
| Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK | 1 |
| Fabbro, D; Manley, PW | 1 |
| Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ | 1 |
| Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC | 1 |
| Almerico, AM; Barraja, P; Cirrincione, G; Dattolo, G; Diana, P; Lauria, A; Montalbano, A | 1 |
| Boger, DL; Coleman, RS; Invergo, BJ; Kitos, PA; Leong, T; McLaughlin, LW; Thompson, SC; Zarrinmayeh, H | 1 |
| Phang, JM | 1 |
| Animati, F; Arcamone, FM; Barbieri, B; Configliacchi, E; D'Alessio, R; Geroni, C; Giuliani, FC; Lazzari, E; Menozzi, M; Mongelli, N | 1 |
| Lalezari, I; Schwartz, EL | 1 |
| Hori, T; Murata, M; Takahashi, E | 1 |
| Hori, T; Ishihara, T; Kaneko, Y; Minamihisamatsu, M; Murata, M; Takahashi, E | 1 |
| Halbrecht, I; Hart, J; Klar, D; Shabtai, F | 1 |
| Capretti, G; Frigerio, G | 1 |
| Sporn, MB | 1 |
| Chandra, P; Gericke, D; Thorbeck, R; Zunino, F | 1 |
| Corrado, L; Felsenfeld, H; Kubilus, J | 1 |
153 review(s) available for pyrroles and Neoplasms
| Article | Year |
|---|---|
Immunogenic Cell Death Induction by Ionizing Radiation.
Topics: Alarmins; Animals; Antigens, Neoplasm; Biomarkers; Combined Modality Therapy; Cytokines; Dose-Response Relationship, Radiation; Ferroptosis; HMGB1 Protein; Humans; Hyperthermia, Induced; Immunogenic Cell Death; Mice; Morpholines; Necroptosis; Neoplasms; Piperazines; Pyrroles; Radiation Tolerance; Radiation, Ionizing | 2021 |
Recent Advances of Diketopyrrolopyrrole Derivatives in Cancer Therapy and Imaging Applications.
Topics: Humans; Ketones; Nanoparticles; Neoplasms; Photochemotherapy; Phototherapy; Pyrroles | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy.
Topics: Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; DNA; Humans; Immunoconjugates; Neoplasms; Pyrroles | 2021 |
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Double-Blind Method; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G1 Phase Cell Cycle Checkpoints; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic | 2020 |
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, Fibroblast Growth Factor | 2020 |
Polymeric immunosensors for tumor detection.
Topics: Aniline Compounds; Biomarkers, Tumor; Biosensing Techniques; Electrochemical Techniques; Electrochemistry; Enzyme-Linked Immunosorbent Assay; Humans; Immunoassay; Ligands; Magnetics; Mutation; Neoplasms; Point-of-Care Systems; Polyhydroxyethyl Methacrylate; Polymers; Pyrroles; Surface Plasmon Resonance; Thermometry | 2020 |
Application of DNA-Alkylating Pyrrole-Imidazole Polyamides for Cancer Treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; DNA; Humans; Imidazoles; Neoplasms; Nylons; Proto-Oncogene Proteins p21(ras); Pyrroles; Telomere | 2021 |
Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Infant; Male; Models, Biological; Neoplasms; Pyrroles; Sunitinib; Young Adult | 2021 |
Small-Molecule Inhibitors Targeting Proteasome-Associated Deubiquitinases.
Topics: Enzyme Inhibitors; Humans; Neoplasm Proteins; Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Pyrroles; Pyrrolidines; Ubiquitin Thiolesterase | 2021 |
Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bridged Bicyclo Compounds, Heterocyclic; Drug Screening Assays, Antitumor; Humans; Indoles; MAP Kinase Signaling System; Mitochondrial Dynamics; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Oncogene Addiction; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2017 |
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Humans; Immune System Diseases; Immunity, Innate; Indoles; Infections; Isoquinolines; Lysosomes; Maprotiline; Metformin; Neoplasms; Phenols; Pyrroles; Resveratrol; Sirolimus; Spermidine; Stilbenes; Tetrahydroisoquinolines; Trehalose | 2017 |
Batzella, Crambe and Monanchora: Highly Prolific Marine Sponge Genera Yielding Compounds with Potential Applications for Cancer and Other Therapeutic Areas.
Topics: Alkaloids; Animals; Antineoplastic Agents; Crambe Sponge; Guanidines; Humans; Molecular Mimicry; Molecular Structure; Neoplasms; Porifera; Pyrroles; Quinolines; Structure-Activity Relationship | 2018 |
Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy.
Topics: Antineoplastic Agents; Drug Design; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2018 |
Benzopyrroloxazines containing a bridgehead nitrogen atom as promising scaffolds for the achievement of biologically active agents.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Bacterial Infections; Chemistry Techniques, Synthetic; Drug Discovery; Humans; Inflammation; Neoplasms; Nitrogen; Oxazines; Pyrroles; Virus Diseases | 2018 |
Managing Risks with Biologics.
Topics: Antibodies, Monoclonal, Humanized; Biological Products; Demyelinating Diseases; Deprescriptions; Drug Substitution; Gastrointestinal Agents; Humans; Infections; Inflammatory Bowel Diseases; Lymphoma; Melanoma; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk; Risk Assessment; Skin Neoplasms; Tumor Necrosis Factor-alpha; Ustekinumab | 2019 |
Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Topics: Anemia; Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Hematologic Diseases; Humans; Incidence; Indoles; Neoplasms; Neutropenia; Publication Bias; Pyrroles; Risk; Sunitinib; Thrombocytopenia | 2013 |
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
A functional scaffold in marine alkaloid: an anticancer moiety for human.
Topics: Alkaloids; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Oxazoles; Pyridines; Pyrroles; Quinolines | 2013 |
BH3 mimetics: status of the field and new developments.
Topics: Amino Acid Motifs; Aniline Compounds; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; Gossypol; Humans; Indoles; Molecular Mimicry; Neoplasms; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Comparative pathophysiology, toxicology, and human cancer risk assessment of pharmaceutical-induced hibernoma.
Topics: Animals; Benzazepines; Carcinogenicity Tests; Disease Models, Animal; Humans; Hydromorphone; Lipoma; Mutagenicity Tests; Neoplasms; Phentolamine; Piperidines; Pyrimidines; Pyrroles; Quinoxalines; Rats; Risk Assessment; Varenicline | 2013 |
Tumor angiogenesis and anti-angiogenic therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factors | 2013 |
The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders.
Topics: Alopecia Areata; Animals; Antibodies, Monoclonal; Autoimmune Diseases; Humans; Interleukin-15; Leukemia-Lymphoma, Adult T-Cell; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-15; Signal Transduction | 2013 |
Sunitinib in the treatment of advanced solid tumors.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Small molecule inhibitors in veterinary oncology practice.
Topics: Animals; Benzamides; Cat Diseases; Cats; Dog Diseases; Dogs; Indoles; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thiazoles | 2014 |
A Short Review on the Synthetic Strategies of Duocarmycin Analogs that are Powerful DNA Alkylating Agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; DNA Methylation; DNA, Neoplasm; Duocarmycins; Humans; Indoles; Molecular Structure; Neoplasms; Pyrroles | 2015 |
Diagnostic and therapeutic implications of the vascular endothelial growth factor family in cancer.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors | 2015 |
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Incidence; Janus Kinase 3; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Drug compound characterization by mass spectrometry imaging in cancer tissue.
Topics: Animals; Antineoplastic Agents; Drug Compounding; Humans; Indoles; Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sunitinib; Xenograft Model Antitumor Assays | 2015 |
Combining radiotherapy with sunitinib: lessons (to be) learned.
Topics: Animals; Chemoradiotherapy; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Marinopyrroles: Unique Drug Discoveries Based on Marine Natural Products.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aquatic Organisms; Bacteria; Biological Products; Cosmetics; Drug Design; Drug Discovery; Europe; Humans; Marine Biology; Methicillin-Resistant Staphylococcus aureus; Neoplasms; Pharmaceutical Preparations; Pyrroles; Seawater; United States; United States Food and Drug Administration | 2016 |
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Indoles; Neoplasms; Pyrroles; Research Design; Sunitinib; Treatment Outcome | 2015 |
A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma.
Topics: Adenosine Triphosphate; Animals; Calreticulin; DNA; Enzyme-Linked Immunosorbent Assay; HMGB1 Protein; Humans; Imidazoles; Immunoblotting; Inflammation; K562 Cells; Luminescence; Lymphoma, B-Cell; Macrophages; Necrosis; Neoplasms; Nylons; Phagocytosis; Pyrroles; Signal Transduction; Telomere; Up-Regulation | 2015 |
Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; Indoles; Neoplasms; Pyrroles; Risk Assessment; Sunitinib; United States; United States Food and Drug Administration | 2016 |
Update on cardiotoxicity of anti-cancer treatments.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bevacizumab; Cardiotoxicity; Echocardiography; Humans; Indoles; Lapatinib; Magnetic Resonance Imaging; Neoplasms; Positron-Emission Tomography; Pyrroles; Quinazolines; Radiation Injuries; Radiotherapy; Sunitinib; Taxoids; Trastuzumab; Troponin; Vinca Alkaloids | 2016 |
An Update on the Synthesis of Pyrrolo[1,4]benzodiazepines.
Topics: Anti-HIV Agents; Antineoplastic Agents; Benzodiazepines; Clinical Trials as Topic; Cyclization; DNA; HIV Infections; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship | 2016 |
Is sunitinib a Narrow Therapeutic Index Drug? - A systematic review and in vitro toxicology-analysis of Sunitinib vs. Imatinib in cells from different tissues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug and Narcotic Control; Drugs, Generic; Humans; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Neoplasms; Organ Specificity; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Signal Transduction; Sunitinib; Toxicity Tests | 2016 |
[Proteasome inhibitors in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Dipeptides; Humans; Lactones; Multiple Myeloma; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Pyrroles; Thiazoles; Threonine | 2015 |
Malignancy and Janus Kinase Inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms | 2017 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
The emerging safety profile of JAK inhibitors in rheumatic disease.
Topics: Azetidines; Humans; Infections; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rheumatic Diseases; Signal Transduction; Sulfonamides | 2017 |
Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Design; Humans; Inflammation; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure | 2017 |
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Neoplasms; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Risk | 2017 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.
Topics: Aniline Compounds; Animals; Apoptosis; Benzamides; Binding Sites; Biphenyl Compounds; Gossypol; Humans; Indoles; Lymphoma; Models, Molecular; Neoplasms; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Sulfones | 2009 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
[Progress in the studies on small molecule IGF-1R inhibitors].
Topics: Animals; Apoptosis; Benzimidazoles; Catechin; Cell Line, Tumor; Humans; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction | 2008 |
[Advances in the study of small peptides in targeted drug delivery system].
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Humans; Neoplasms; Oligopeptides; Pyrroles; Receptors, Bombesin; Receptors, LHRH; Receptors, Somatostatin | 2008 |
Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Enzyme Inhibitors; Humans; Hypoxia-Inducible Factor 1; Indoles; Intercellular Signaling Peptides and Proteins; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Phenylpropionates; Pyrroles; Sunitinib | 2009 |
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Gossypol; Humans; Indoles; Mitochondria; Neoplasms; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Thionucleotides | 2009 |
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Indoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Targeting the proteasome pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Biological Products; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Discovery; Humans; Lactones; Neoplasms; Peptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Ubiquitin; Ubiquitin-Activating Enzymes; Ubiquitins | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib in solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Molecular Structure; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Mimicking the BH3 domain to kill cancer cells.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding, Competitive; Biphenyl Compounds; Clinical Trials as Topic; Dimerization; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indoles; Mice; Mitochondria; Multigene Family; Neoplasm Proteins; Neoplasms; Nitrophenols; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thionucleotides | 2008 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
An overview of small-molecule inhibitors of VEGFR signaling.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States | 2009 |
Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
Topics: Animals; Drug Delivery Systems; Genetic Therapy; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2009 |
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Carcinoma, Renal Cell; Endpoint Determination; Fatigue; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Neutrophils; Nonlinear Dynamics; Population; Pyrroles; Sunitinib | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Interactions; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Neoplasms; Pyrroles; Sunitinib | 2010 |
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Topics: Animals; Antineoplastic Agents; CD11b Antigen; Humans; Immune Tolerance; Immunotherapy; Indoles; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2011 |
The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromosome Aberrations; Chromosomes, Human, Pair 2; Drug Synergism; Gene Amplification; Humans; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Mutation; Neoplasms; Neuroblastoma; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1 | 2010 |
New insights on the antitumoral properties of prodiginines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Damage; Humans; Indoles; Neoplasms; Prodigiosin; Pyrroles; Serratia; Signal Transduction | 2010 |
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
Topics: Animals; Drug Design; Enzyme Inhibitors; Fermentation; Humans; Lactones; Neoplasms; Proteasome Inhibitors; Pyrroles; Technology, Pharmaceutical | 2010 |
[Treatment with antiangiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Indoles; Neoplasms; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Anti-angiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib | 2010 |
Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Targeting apoptosis pathways by natural compounds in cancer: marine compounds as lead structures and chemical tools for cancer therapy.
Topics: Alkaloids; Alkanes; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Aquatic Organisms; Biological Products; Bryostatins; Carbamates; Cell Proliferation; Depsipeptides; Dioxoles; Drug Screening Assays, Antitumor; Humans; Lactones; Macrolides; Microtubules; Models, Chemical; Neoplasms; Phenanthrolines; Phenazines; Proteasome Endopeptidase Complex; Pyrones; Pyrroles; Quinolines; Spiro Compounds; Steroids; Tetrahydroisoquinolines; Thiazoles; Trabectedin | 2013 |
Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides | 2010 |
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Cysteine Proteinase Inhibitors; Humans; Lactones; Molecular Conformation; Neoplasms; Proteasome Inhibitors; Pyrroles | 2010 |
Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Topics: Anaplastic Lymphoma Kinase; Animals; Crizotinib; Genetic Predisposition to Disease; Humans; Molecular Structure; Mutation; Neoplasms; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases | 2010 |
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Topics: Alanine; Clinical Trials as Topic; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Doxorubicin; Drug Delivery Systems; ErbB Receptors; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Lymphoma, Large B-Cell, Diffuse; Mutation; Neoplasms; Piperazines; Prednisone; Pyrimidines; Pyrroles; Remission Induction; Rituximab; Sunitinib; Vincristine | 2010 |
Role of tyrosine kinase inhibitors in tumor immunology.
Topics: Animals; Antigen-Presenting Cells; Antineoplastic Agents; Dendritic Cells; Humans; Indoles; Mice; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2011 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
Topics: Allosteric Regulation; Antineoplastic Agents; Drug Discovery; Humans; Kinesins; Neoplasms; Piperidines; Pyrroles; Taxoids | 2010 |
Myeloid derived suppressor cells in human diseases.
Topics: Animals; Biomarkers; Humans; Immunosuppression Therapy; Indoles; Inflammatory Bowel Diseases; Mice; Molecular Targeted Therapy; Myeloid Cells; Myelopoiesis; Neoplasms; Pyrroles; Sunitinib; Tretinoin | 2011 |
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Lactones; Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrroles | 2011 |
Brivanib alaninate for cancer.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
The development of pyrrolobenzodiazepines as antitumour agents.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Benzodiazepinones; DNA Damage; Drug Delivery Systems; Drug Design; Humans; Neoplasms; Pyrroles; Structure-Activity Relationship | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Novel proteasome inhibitors to overcome bortezomib resistance.
Topics: Allosteric Site; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Chloroquine; Clioquinol; Drug Resistance, Neoplasm; Humans; Hydroxyquinolines; Lactones; Neoplasms; Oligopeptides; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Threonine; Ubiquitinated Proteins; Ubiquitination | 2011 |
Discovery of carboxyethylpyrroles (CEPs): critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids.
Topics: Animals; Antibodies; Autistic Disorder; CD36 Antigens; Cornea; Corneal Neovascularization; Endothelial Cells; Humans; Macular Degeneration; Mice; Mice, Knockout; Neoplasms; Oxidation-Reduction; Phospholipids; Protein Processing, Post-Translational; Pyrroles; Retinal Rod Photoreceptor Cells; Toll-Like Receptor 2; Wound Healing | 2011 |
Sunitinib-induced asthenia: from molecular basis to clinical relief.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Asthenia; Gene Expression Regulation; Humans; Incidence; Indoles; Neoplasms; Pyrroles; Severity of Illness Index; Signal Transduction; Sunitinib | 2011 |
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Confounding Factors, Epidemiologic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Interferon-gamma; Neoplasms; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Treatment Outcome | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Bcl-2 inhibitors: emerging drugs in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Gossypol; Humans; Indoles; Models, Biological; Molecular Mimicry; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2012 |
Small molecule drugs - optimizing DNA damaging agent-based therapeutics.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzodiazepinones; Dioxoles; DNA; DNA Damage; Humans; Neoplasms; Nitrogen Mustard Compounds; Pyrroles; Tetrahydroisoquinolines; Trabectedin | 2012 |
Targeting the B-cell lymphoma/leukemia 2 family in cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Thionucleotides; Treatment Outcome | 2012 |
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Indoles; Neoplasms; Piperidines; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Thiazoles | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
Topics: Animals; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Indoles; Mice; Myeloid Progenitor Cells; Neoplasms; Organ Specificity; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; STAT3 Transcription Factor; STAT5 Transcription Factor; Sunitinib; T-Lymphocytes; Tumor Escape | 2012 |
Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis.
Topics: Algorithms; Antineoplastic Agents; Humans; Hypothyroidism; Incidence; Indoles; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sunitinib | 2013 |
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Angiostatins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose Fractionation, Radiation; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Esophageal Neoplasms; Farnesyltranstransferase; Female; Head and Neck Neoplasms; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Laryngeal Neoplasms; Lung Neoplasms; Lymphokines; Male; Membrane Proteins; Neoplasms; Peptide Fragments; Plasminogen; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Tyrosine kinases as targets in cancer therapy - successes and failures.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2003 |
Recent developments in novel pyrrolo[2,1-c][1,4]benzodiazepine conjugates: synthesis and biological evaluation.
Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Chemical Phenomena; Chemistry, Physical; DNA; Drug Screening Assays, Antitumor; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Neoplasms; Pyrroles; RNA; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Brostallicin: a new concept in minor groove DNA binder development.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Distamycins; DNA; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Glutathione; Glutathione Transferase; Guanidines; Humans; Molecular Structure; Neoplasms; Pyrroles | 2004 |
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2004 |
Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Neoplasms; Pyrroles | 2004 |
Antitumor activity of HER-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2005 |
Sunitinib malate for the treatment of solid tumours: a review of current clinical data.
Topics: Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2006 |
Anti-angiogenic and anti-HER therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2006 |
Sunitinib: a newly approved small-molecule inhibitor of angiogenesis.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Humans; In Vitro Techniques; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; United States; United States Food and Drug Administration | 2006 |
Targeting ubiquitin in cancers.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Communication; Cell Cycle; Genetic Therapy; Heat-Shock Proteins; Humans; Lactones; Neoplasms; Pyrazines; Pyrroles; Ubiquitin | 2006 |
Sunitinib: from rational design to clinical efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Design; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Leukemia, Myeloid, Acute; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2007 |
PDGF receptors as targets in tumor treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Design of clinical trials of radiation combined with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
Molecular basis for sunitinib efficacy and future clinical development.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Endothelial Cells; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Role of focal adhesion kinase in human cancer: a potential target for drug discovery.
Topics: Animals; Drug Design; Focal Adhesion Protein-Tyrosine Kinases; Humans; Mice; Neoplasms; Pyrimidines; Pyrroles; RNA, Small Interfering | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
The photochemistry of carotenoids. Some photosynthetic and photomedical aspects.
Topics: Carotenoids; Humans; Molecular Structure; Neoplasms; Photochemistry; Photosynthesis; Porphyrins; Pyrroles; Radiation Protection; Tetrapyrroles | 1993 |
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
Su-6668. SUGEN.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship | 2001 |
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles | 2002 |
A demonstration of the intrinsic importance of stabilizing hydrophobic binding and non-covalent van der Waals contacts dominant in the non-covalent CC-1065/B-DNA binding.
Topics: Animals; Antibiotics, Antineoplastic; Base Sequence; Carbamates; Chemical Phenomena; Chemistry, Physical; DNA; Duocarmycins; Humans; Indoles; Leucomycins; Macromolecular Substances; Molecular Conformation; Molecular Sequence Data; Molecular Structure; Neoplasms; Nucleic Acid Conformation; Pyrroles; Structure-Activity Relationship | 1990 |
The regulatory functions of proline and pyrroline-5-carboxylic acid.
Topics: Amino Acids; Animals; Biological Transport; Cell Communication; Cell Cycle; Charcoal; Glutamates; Glutamic Acid; Humans; Mitosis; NADP; Neoplasms; Ornithine; Oxidation-Reduction; Phosphoribosyl Pyrophosphate; Proline; Protein Biosynthesis; Purine Nucleotides; Pyrroles; Structure-Activity Relationship | 1985 |
Plant phenolics as inhibitors of mutational and precarcinogenic events.
Topics: Animals; Carcinogens; Diet; Humans; Mutation; Neoplasms; Phenols; Plant Extracts; Plants, Edible; Porphyrins; Pyrroles | 1987 |
[Molecular basis of viral induced tumors (author's transl)].
Topics: Amidines; Animals; Anti-Bacterial Agents; Cell Transformation, Neoplastic; Daunorubicin; DNA Nucleotidyltransferases; DNA Viruses; Doxorubicin; Humans; Neoplasms; Oncogenic Viruses; Peptides; Pyrroles; RNA Viruses | 1973 |
91 trial(s) available for pyrroles and Neoplasms
| Article | Year |
|---|---|
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Topics: Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Neoplasms; Pyrimidines; Pyrroles; Tumor Suppressor Protein p53 | 2022 |
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Humans; Immune Checkpoint Inhibitors; Indoles; Lung Neoplasms; Neoplasms; Nivolumab; Pyrroles; Pyrrolidines | 2022 |
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Topics: Acetonitriles; Humans; Neoplasms; Oximes; Pyrazoles; Pyrimidines; Pyrroles; Pyrrolidines; Sulfonamides; Tumor Microenvironment | 2022 |
First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors.
Topics: Class I Phosphatidylinositol 3-Kinases; Humans; Neoplasms; Piperazines; Pyrroles | 2022 |
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
Topics: Adult; East Asian People; Humans; Morpholines; Neoplasms; Pyrimidines; Pyrroles; Young Adult | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Topics: Adult; Carcinoma, Adenoid Cystic; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles | 2023 |
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
Topics: Adult; Aged; Apoptosis Regulatory Proteins; Female; Follow-Up Studies; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Piperazines; Prognosis; Pyrroles | 2020 |
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Analgesics; Anti-Bacterial Agents; Antineoplastic Agents; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Skin; Steroids; Young Adult | 2021 |
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Everolimus; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; MTOR Inhibitors; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Pyrrolidines; Receptors, Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2021 |
Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
Topics: Dose-Response Relationship, Drug; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; Neoplasms; Pyrimidines; Pyrroles | 2022 |
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Topics: Animals; Carboplatin; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Indoles; Male; Neoplasms; Pyrroles | 2018 |
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Capsules; Cross-Over Studies; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Neoplasms; Pyrimidines; Pyrroles; Tablets | 2018 |
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Long QT Syndrome; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2018 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.
Topics: Animals; Antineoplastic Agents; Apoptosis; Area Under Curve; bcl-X Protein; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Screening Assays, Antitumor; Humans; Imidazoles; Kaplan-Meier Estimate; Maximum Tolerated Dose; Mice; Neoplasm Transplantation; Neoplasms; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; RNA, Small Interfering; Time Factors; Tumor Suppressor Protein p53 | 2018 |
Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Patient Safety; Prognosis; Protein Kinase Inhibitors; Pyrroles; Pyrrolidines; Survival Rate; Tissue Distribution | 2019 |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Non-Randomized Controlled Trials as Topic; Prognosis; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tissue Distribution; Young Adult | 2020 |
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2013 |
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biotransformation; Carcinoma, Renal Cell; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Postprandial Period; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma; Young Adult | 2013 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Ritonavir; Sunitinib | 2014 |
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Indoles; Lomustine; Neoplasms; Pyrroles | 2016 |
Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Male; Middle Aged; Neoplasms; Nervous System Diseases; Pilot Projects; Protein Kinase Inhibitors; Pyrroles; Salvage Therapy; Sunitinib | 2014 |
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Female; Gastrointestinal Hormones; Humans; Indoles; Male; Middle Aged; Neoplasms; Neuropeptides; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Double-Blind Method; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Pilot Projects; Piperazines; Placebos; Protein Kinase Inhibitors; Purines; Pyrroles; Sildenafil Citrate; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Topics: Aged; Angiogenesis Inhibitors; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Body Weight; Constitutive Androstane Receptor; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrroles; Receptors, Steroid; Sunitinib; Treatment Outcome | 2015 |
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gene Expression; Hedgehog Proteins; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Pyridines; Pyrroles; Retreatment; RNA, Messenger; Signal Transduction; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2015 |
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Agents; Chronotherapy; Circadian Rhythm; Cross-Over Studies; Drug Evaluation, Preclinical; Female; Humans; Indoles; Male; Mice; Middle Aged; Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2015 |
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
Topics: Antineoplastic Agents; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cell Survival; Disease Progression; Flow Cytometry; Humans; Immune System; Immunosuppressive Agents; Indoles; Leukocytes, Mononuclear; Monocytes; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Phosphorylation; Pyrroles; Radiosurgery; Sialic Acid Binding Ig-like Lectin 3; STAT3 Transcription Factor; Sunitinib; Treatment Outcome | 2015 |
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Doxycycline; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice, Nude; Mutation, Missense; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Administration Schedule; Epothilones; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tubulin Modulators | 2016 |
Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles | 2016 |
Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2016 |
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lactones; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Proteasome Inhibitors; Pyrroles; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Dog Diseases; Dogs; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Flow Cytometry; Indoles; Male; Neoplasms; Neutropenia; Pyrroles | 2017 |
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Prospective Studies; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; von Hippel-Lindau Disease | 2016 |
Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzodiazepinones; DNA; Histones; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles | 2009 |
Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Patient Compliance; Pyrroles; Radiation Dosage; Sunitinib | 2009 |
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Tumor Burden | 2009 |
Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib.
Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Aza Compounds; Dose-Response Relationship, Drug; Electrocardiography; Fluoroquinolones; Granisetron; Heart Ventricles; Humans; Indoles; Moxifloxacin; Neoplasms; Placebos; Protein-Tyrosine Kinases; Pyrroles; Quinolines; Risk; Sunitinib; Time Factors | 2009 |
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Half-Life; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Taxoids | 2010 |
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Guanidines; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pyrroles; Sex Characteristics | 2010 |
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Female; Humans; Ifosfamide; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Pyrroles; Sunitinib | 2010 |
Marginal increase of sunitinib exposure by grapefruit juice.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Labeling; Female; Food-Drug Interactions; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2011 |
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Indoles; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Remission Induction | 2010 |
Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Aged; Alanine; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Feces; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Pyrroles; Triazines | 2010 |
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Plasminogen Activator Inhibitor 1; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A | 2011 |
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles | 2011 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vomiting; Young Adult | 2010 |
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Feasibility Studies; Female; Glutamates; Guanine; Humans; Indoles; Japan; Male; Middle Aged; Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.
Topics: Adult; Aged; Cells, Cultured; Cyclin-Dependent Kinases; Disease Susceptibility; Female; Herpesviridae; Herpesviridae Infections; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Pyrazoles; Pyrroles; Signal Transduction; Toll-Like Receptors | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Benzodiazepinones; Dexamethasone; Dyspnea; Edema; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles | 2011 |
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; CDC2 Protein Kinase; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles | 2011 |
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Infusions, Intravenous; Kinesins; Leukocyte Count; Male; Middle Aged; Neoplasms; Piperidines; Pyrroles; Young Adult | 2012 |
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2011 |
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Heart; Humans; Indoles; Male; Maximum Tolerated Dose; Neoplasms; Neutropenia; Pyrroles; Sunitinib | 2011 |
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Dideoxynucleosides; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Indoles; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasms; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Humans; Indoles; Neoplasms; Powders; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Young Adult | 2012 |
Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Indoles; Male; Neoplasms; Piroxicam; Protein-Tyrosine Kinases; Pyrroles | 2012 |
Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction.
Topics: Chromatography, Liquid; Cyclohexanes; Dose-Response Relationship, Drug; Drug Stability; Humans; Linear Models; Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2013 |
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Indoles; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Pyrroles; Radiotherapy, Image-Guided; Sunitinib; Survival Rate | 2012 |
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2012 |
A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Positron-Emission Tomography; Pyrroles; Triazines | 2012 |
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib | 2012 |
A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Boronic Acids; Bortezomib; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines; Pyrroles; Sunitinib; Thyroid Neoplasms | 2013 |
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Endothelial Growth Factors; Fatigue; Female; Fibroblast Growth Factor 2; Headache; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Molecular Structure; Nausea; Neoplasms; Pyrroles; Salvage Therapy; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vomiting | 2002 |
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Indoles; Inhibitory Concentration 50; Male; Models, Chemical; Mutation; Neoplasms; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Time Factors; Tomography, X-Ray Computed | 2003 |
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Topics: Adult; Aged; Area Under Curve; DNA-Binding Proteins; Female; Guanidines; Humans; Infusions, Intravenous; Intercalating Agents; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Pyrroles | 2003 |
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Calibration; DNA Damage; Female; Guanidines; Humans; Kinetics; Male; Middle Aged; Models, Chemical; Neoplasms; Pyrroles; Time Factors | 2004 |
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Oxindoles; Propionates; Pyrroles; Time Factors; Tomography, X-Ray Computed | 2004 |
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles | 2005 |
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Topics: Absorption; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Software; Time Factors; Vascular Endothelial Growth Factor A | 2005 |
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Endpoint Determination; Female; Humans; Indoles; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles | 2005 |
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Topics: Administration, Oral; Adult; Drug Administration Schedule; Female; Humans; Indoles; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2006 |
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Female; Humans; Hypertension; Indoles; Male; Middle Aged; Neoplasms; Pigmentation; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sunitinib | 2006 |
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein Binding; Pyrroles | 2006 |
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Blood Pressure; Dose-Response Relationship, Drug; Fatigue; Female; Follow-Up Studies; Heart Rate; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Pancreas; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Relative analgesic potency of oral zomepirac and intramuscular morphine in cancer patients with postoperative pain.
Topics: Administration, Oral; Adult; Analgesics; Clinical Trials as Topic; Female; Humans; Injections, Intramuscular; Male; Morphine; Neoplasms; Pain, Postoperative; Pyrroles; Tolmetin | 1980 |
Double-blind comparisons of zomepirac and oxycodone with APC in cancer pain.
Topics: Adult; Analgesics; Aspirin; Caffeine; Clinical Trials as Topic; Codeine; Double-Blind Method; Drug Combinations; Female; Humans; Male; Neoplasms; Oxycodone; Pain; Phenacetin; Pyrroles; Tolmetin | 1980 |
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome | 2002 |
[Controlled clinical study of the analgesic activity of a new drug (Z. 424) in pain caused by neoplasms].
Topics: Adult; Aged; Analgesics; Benzyl Compounds; Blood Pressure; Butylamines; Codeine; Digestive System; Ethanolamines; Female; Heart Rate; Humans; Middle Aged; Neoplasms; Palliative Care; Placebos; Pyrroles | 1970 |
352 other study(ies) available for pyrroles and Neoplasms
| Article | Year |
|---|---|
Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
Topics: Animals; Benzamides; Butyric Acid; Cachexia; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Heart Diseases; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Pyridines; Pyrroles | 2022 |
Polypyrrole-based nanotheranostic agent for MRI guided photothermal-chemodynamic synergistic cancer therapy.
Topics: Animals; Hydrogen Peroxide; Magnetic Resonance Imaging; Manganese Compounds; Mice; Neoplasms; Oxides; Polymers; Pyrroles; Theranostic Nanomedicine | 2021 |
Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.
Topics: Animals; Dog Diseases; Dogs; Indoles; Mast Cells; Neoplasms; Pyrroles; Retrospective Studies; Vinblastine | 2021 |
Gold nanorod@void@polypyrrole yolk@shell nanostructures: Synchronous regulation of photothermal and drug delivery performance for synergistic cancer therapy.
Topics: Cell Line, Tumor; Doxorubicin; Gold; Humans; Nanotubes; Neoplasms; Pharmaceutical Preparations; Phototherapy; Polymers; Pyrroles; Tumor Microenvironment | 2022 |
Dual-template rectangular nanotube molecularly imprinted polypyrrole for label-free impedimetric sensing of AFP and CEA as lung cancer biomarkers.
Topics: alpha-Fetoproteins; Biomarkers, Tumor; Biosensing Techniques; Carcinoembryonic Antigen; Electrochemical Techniques; Electrodes; Humans; Limit of Detection; Lung; Molecular Imprinting; Nanotubes; Neoplasms; Polymers; Pyrroles | 2022 |
USP14 Regulates Cancer Cell Growth in a Fatty Acid Synthase-Independent Manner.
Topics: A549 Cells; Cell Proliferation; Fatty Acid Synthase, Type I; HEK293 Cells; Humans; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Pyrroles; Pyrrolidines; Ubiquitin Thiolesterase; Ubiquitination | 2021 |
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2022 |
Tumor acidity-activatable photothermal/Fenton nanoagent for synergistic therapy.
Topics: Cell Line, Tumor; Humans; Hydroxyl Radical; Nanoparticles; Neoplasms; Polymers; Pyrroles; Theranostic Nanomedicine | 2022 |
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Humans; Immunoconjugates; Mice; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays | 2022 |
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Topics: Aminopyridines; Area Under Curve; Humans; Liver Diseases; Multiple Organ Failure; National Cancer Institute (U.S.); Neoplasms; Pyrroles; United States | 2022 |
Synthesis Strategies and Medicinal Value of Pyrrole and its Fused Heterocyclic Compounds.
Topics: Antiviral Agents; COVID-19; Heterocyclic Compounds; Humans; Neoplasms; Pyrroles | 2022 |
Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study.
Topics: Etanercept; Herpes Zoster; Herpesvirus 3, Human; Humans; Neoplasms; Piperidines; Pyrimidines; Pyrroles | 2022 |
Chidamide stacked in magnetic polypyrrole nano-composites counter thermotolerance and metastasis for visualized cancer photothermal therapy.
Topics: Aminopyridines; Animals; Benzamides; Magnetic Resonance Imaging; Mice; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Thermotolerance | 2022 |
Boosting nutrient starvation-dominated cancer therapy through curcumin-augmented mitochondrial Ca
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Curcumin; Glucose; Humans; Indoles; Neoplasms; Nutrients; Pyrroles; Starvation | 2022 |
Magnetic-targeted capacitive heterostructure of polypyrrole for hypoxia-tolerant synergistic photodynamic/photothermal therapy under near infrared excitation.
Topics: Animals; Cell Line, Tumor; Hydrogen Peroxide; Hypoxia; Magnetic Phenomena; Mice; Mice, Nude; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polymers; Pyrroles; Silicon Dioxide | 2022 |
Polypyrrole Nanoenzymes as Tumor Microenvironment Modulators to Reprogram Macrophage and Potentiate Immunotherapy.
Topics: Glutathione; Humans; Hyperthermia, Induced; Immunologic Factors; Immunotherapy; Macrophages; Neoplasms; Polymers; Pyrroles; Tumor Microenvironment | 2022 |
Discovery and Optimization of Pyrrolopyrimidine Derivatives as Selective Disruptors of the Perinucleolar Compartment, a Marker of Tumor Progression toward Metastasis.
Topics: Biomarkers; Cell Nucleolus; Cell Nucleus; Humans; Neoplasms; Pyrimidines; Pyrroles | 2022 |
Fabrication of methylene blue-loaded ovalbumin/polypyrrole nanoparticles for enhanced phototherapy-triggered antitumour immune activation.
Topics: Humans; Methylene Blue; Nanoparticles; Neoplasms; Ovalbumin; Phototherapy; Polymers; Pyrroles | 2022 |
2-Amino-Pyrrole-Carboxylate Attenuates Homology-Mediated DNA Repair and Sensitizes Cancer Cells to Doxorubicin.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; Doxorubicin; Humans; Neoplasms; Paclitaxel; Pyrroles | 2022 |
Novel Donor-Acceptor Conjugated Polymer-Based Nanomicelles for Photothermal Therapy in the NIR Window.
Topics: Animals; Humans; Mice; Micelles; Nanoparticles; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Pyrroles | 2022 |
Topics: Copper; Humans; Nanoparticles; Neoplasms; Photoacoustic Techniques; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Temperature; Theranostic Nanomedicine | 2022 |
Constructing Hypoxia-Tolerant and Host Tumor-Enriched Aggregation-Induced Emission Photosensitizer for Suppressing Malignant Tumors Relapse and Metastasis.
Topics: Humans; Hypoxia; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Reactive Oxygen Species; Recurrence | 2022 |
A Water-Stable and Red-Emissive Radical Cation for Mutp53 Cancer Therapy.
Topics: Cations; Humans; Mutant Proteins; Neoplasms; Pyrroles; Tumor Suppressor Protein p53; Water | 2022 |
Green synthesis of gold nanoparticles using plant products and plants extracts aiming for cancer therapy: helping the beauty to beat 'cure' the beast.
Topics: Gold; Green Chemistry Technology; Humans; Metal Nanoparticles; Neoplasms; Plant Extracts; Polymers; Pyrroles | 2022 |
Targeted Wolfram-Doped Polypyrrole for Photonic Hyperthermia-Synergized Radiotherapy.
Topics: Cell Line, Tumor; Humans; Hyperthermia; Hyperthermia, Induced; Neoplasms; Polymers; Pyrroles; Radiation-Sensitizing Agents; Tungsten | 2022 |
Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells.
Topics: Endothelial Growth Factors; Humans; Molecular Docking Simulation; Neoplasms; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles | 2023 |
Smart Chemical Oxidative Polymerization Strategy To Construct Au@PPy Core-Shell Nanoparticles for Cancer Diagnosis and Imaging-Guided Photothermal Therapy.
Topics: Gold; Humans; Nanoparticles; Neoplasms; Oxidative Stress; Phototherapy; Photothermal Therapy; Polymerization; Polymers; Pyrroles; Theranostic Nanomedicine | 2023 |
Photonic Hyperthermia Synergizes with Immune-Activators to Augment Tumor-Localized Immunotherapy.
Topics: Humans; Hyperthermia; Hyperthermia, Induced; Immunotherapy; Neoplasms; Phototherapy; Polymers; Pyrroles; Tumor Microenvironment | 2023 |
Hybrid Polypyrrole and Polydopamine Nanosheets for Precise Raman/Photoacoustic Imaging and Photothermal Therapy.
Topics: Humans; Nanoparticles; Neoplasms; Photoacoustic Techniques; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2023 |
Multiple therapeutic mechanisms of pyrrolic N-rich g-C
Topics: Cell Line, Tumor; Copper; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Oxygen; Photochemotherapy; Photosensitizing Agents; Pyrroles; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Covalent Organic Framework-Based Nanomotor for Multimodal Cancer Photo-Theranostics.
Topics: Cell Line, Tumor; Humans; Metal-Organic Frameworks; Neoplasms; Polymers; Precision Medicine; Pyrroles | 2023 |
A new screening tool for FGFR inhibitor treatment?
Topics: Early Detection of Cancer; Humans; Neoplasms; Piperazines; Pyrroles; RNA, Messenger; Thiophenes | 2019 |
Rational Design of BODIPY-Diketopyrrolopyrrole Conjugated Polymers for Photothermal Tumor Ablation.
Topics: Animals; Boron Compounds; Density Functional Theory; HeLa Cells; Humans; Hyperthermia, Induced; Ketones; Mice; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Tumor Burden | 2019 |
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Dogs; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Male; Mice; Molecular Conformation; Neoplasms; Oxazines; Protein Kinase Inhibitors; Pyrimidinones; Pyrroles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; TOR Serine-Threonine Kinases | 2019 |
NIR- and thermo-responsive semi-interpenetrated polypyrrole nanogels for imaging guided combinational photothermal and chemotherapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Contrast Media; Diagnostic Imaging; Drug Delivery Systems; Female; Hot Temperature; Humans; Methotrexate; Mice, Nude; Nanogels; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles | 2019 |
Polymeric Bis(dipyrrinato) Zinc(II) Nanoparticles as Selective Imaging Probes for Lysosomes of Cancer Cells.
Topics: A549 Cells; Cell Line; Coordination Complexes; Fluorescent Dyes; HeLa Cells; Humans; Lysosomes; Microscopy, Confocal; Nanoparticles; Neoplasms; Optical Imaging; Polymers; Pyrroles; Zinc | 2019 |
Investigation of thyroid function in dogs treated with the tyrosine kinase inhibitor toceranib.
Topics: Animals; Dog Diseases; Dogs; Female; Hypothyroidism; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Thyroid Gland; Thyrotropin; Thyroxine; United Kingdom | 2020 |
Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Mice; Neoplasms; Positron-Emission Tomography; Pyrroles; Thiazoles; Xenograft Model Antitumor Assays | 2019 |
NIR-II-Excited Intravital Two-Photon Microscopy Distinguishes Deep Cerebral and Tumor Vasculatures with an Ultrabright NIR-I AIE Luminogen.
Topics: Animals; Blood Vessels; Brain; Cell Survival; Fluorescent Dyes; HeLa Cells; Humans; Mice, Inbred BALB C; Microscopy, Fluorescence, Multiphoton; Neoplasms; Pyrroles; Quantum Dots; Spectroscopy, Near-Infrared; Thiadiazoles; Tissue Distribution | 2019 |
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Topics: Amides; Animals; Antineoplastic Agents; Biosynthetic Pathways; Cell Line, Tumor; CHO Cells; Cricetulus; Folate Receptor 1; Folic Acid Antagonists; Humans; Models, Molecular; Neoplasms; Purine Nucleotides; Pyridines; Pyrroles | 2019 |
TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Biliary Tract Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunoconjugates; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogenes; Proto-Oncogene Proteins c-met; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach Neoplasms; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2020 |
Pyrrole derivatives as potential anti-cancer therapeutics: synthesis, mechanisms of action, safety.
Topics: Animals; Antineoplastic Agents; Antioxidants; Blood Platelets; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Hemoglobins; Humans; Male; Monocytes; Neoplasms; Pyrroles; Rats; Rats, Wistar; Receptors, Vascular Endothelial Growth Factor; Superoxide Dismutase | 2020 |
Deciphering the molecular mechanism of FLT3 resistance mutations.
Topics: Aminopyridines; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Mutation; Neoplasms; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Pyrroles | 2020 |
Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate.
Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Drug Design; Female; Folate Receptors, GPI-Anchored; HeLa Cells; Humans; Mice, Nude; Neoplasms; Prodrugs; Pyrroles; Xenograft Model Antitumor Assays | 2020 |
Potential 2,4-dimethyl-1H-pyrrole-3-carboxamide bearing benzimidazole template: Design, synthesis, in vitro anticancer and in silico ADME study.
Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Models, Molecular; Neoplasms; Pyrroles; Structure-Activity Relationship | 2020 |
Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
Topics: Animals; Antineoplastic Agents; Contrast Media; Cross-Sectional Studies; Dog Diseases; Dogs; Female; Humans; Indoles; Male; Neoplasms; Pyrroles; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
Topics: Adenocarcinoma; Animals; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dog Diseases; Dogs; Female; Indoles; Male; Neoplasm Recurrence, Local; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Topics: Administration, Oral; Animals; Cell Line, Tumor; Female; Half-Life; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Morpholines; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Nude; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Xenograft Model Antitumor Assays | 2020 |
Precisely Tuning Photothermal and Photodynamic Effects of Polymeric Nanoparticles by Controlled Copolymerization.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Infrared Rays; Mice; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polymerization; Polymers; Pyrroles; Reactive Oxygen Species | 2020 |
Scalable dextran-polypyrrole nano-assemblies with photothermal/photoacoustic dual capabilities and enhanced biocompatibility.
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Dextrans; Human Umbilical Vein Endothelial Cells; Humans; Mice, Inbred BALB C; Nanostructures; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles | 2020 |
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Topics: Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Humans; Janus Kinase Inhibitors; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Treatment Outcome | 2021 |
Synthesis and biological evaluation of substituted pyrrolidines and pyrroles as potential anticancer agents.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Jurkat Cells; Molecular Structure; Neoplasms; PC-3 Cells; Pyrroles; Pyrrolidines; Structure-Activity Relationship; Time Factors | 2020 |
Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]-2-ones and their antituberculosis and anticancer activity.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Design; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Melanoma, Experimental; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Neoplasms; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2020 |
Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression.
Topics: A549 Cells; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Imidazoles; Neoplasms; Nylons; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrroles | 2020 |
A Hybrid Organo-Nanotheranostic Platform of Superlative Biocompatibility for Near-Infrared-Triggered Fluorescence Imaging and Synergistically Enhanced Ablation of Tumors.
Topics: Animals; Cell Line, Tumor; Indocyanine Green; Mice; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2020 |
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Molecular; Neoplasms; Pyridines; Pyridones; Pyrroles; Transcription Factors | 2021 |
Fabrication of electrochemical immunosensor based on acid-substituted poly(pyrrole) polymer modified disposable ITO electrode for sensitive detection of CCR4 cancer biomarker in human serum.
Topics: Antibodies, Immobilized; Biomarkers, Tumor; Biosensing Techniques; Electrochemical Techniques; Electrodes; Humans; Immunoassay; Limit of Detection; Neoplasms; Polymers; Pyrroles; Receptors, CCR4; Reproducibility of Results; Tin Compounds | 2021 |
BF
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Fluorescent Dyes; Mice; Mice, Nude; Nanoparticles; Neoplasms; Particle Size; Photothermal Therapy; Pyrroles; Spectroscopy, Near-Infrared; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Homologous | 2020 |
The challenge of drug approval in rare cancers.
Topics: Drug Approval; Humans; Neoplasms; Pyrroles | 2021 |
Heavy-Atom-Free Photosensitizers: From Molecular Design to Applications in the Photodynamic Therapy of Cancer.
Topics: Boron; Boron Compounds; Drug Design; Humans; Light; Naphthalimides; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Quantum Theory; Singlet Oxygen | 2021 |
Metal-Free Organo-Theranostic Nanosystem with High Nitroxide Stability and Loading for Image-Guided Targeted Tumor Therapy.
Topics: Cell Line, Tumor; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Nanoparticles; Neoplasms; Nitrogen Oxides; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2021 |
A PI polyamide-TPP conjugate targeting a mtDNA mutation induces cell death of cancer cells with the mutation.
Topics: Cell Survival; DNA, Mitochondrial; HeLa Cells; Humans; Imidazoles; Mitochondria; Mitophagy; Mutation; Neoplasms; Nylons; Pyrroles; Reactive Oxygen Species; Sulfonium Compounds; Surface Plasmon Resonance | 2021 |
A Highly Efficient One-for-All Nanodroplet for Ultrasound Imaging-Guided and Cavitation-Enhanced Photothermal Therapy.
Topics: Animals; Contrast Media; Female; Fluorocarbons; HeLa Cells; Humans; Mice, Inbred BALB C; Microbubbles; Nanostructures; Neoplasms; Neoplasms, Experimental; Phase Transition; Photoacoustic Techniques; Photothermal Therapy; Polymers; Pyrroles; Ultrasonography; Xenograft Model Antitumor Assays | 2021 |
Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoniazid; Latent Tuberculosis; Leukocytes, Mononuclear; Manganese Compounds; Methylene Blue; Microscopy, Confocal; Mycobacterium tuberculosis; Nanocomposites; Nanoparticles; Neoplasms; Oxides; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Polyethylene Glycols; Polymers; Prospective Studies; Pyrroles; Tuberculin Test; Tuberculosis; Tumor Microenvironment | 2021 |
Iron Self-Boosting Polymer Nanoenzyme for Low-Temperature Photothermal-Enhanced Ferrotherapy.
Topics: Animals; Antineoplastic Agents; Carboxylic Acids; Catalysis; Female; Ferroptosis; HeLa Cells; Humans; Hydrogen Peroxide; Hydroxyl Radical; Iron; Light; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasms; Photosensitizing Agents; Photothermal Therapy; Polymers; Pyrroles; Temperature | 2021 |
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Cell Proliferation; Epitopes; Ethylenediamines; Gene Expression Regulation, Neoplastic; Hematopoiesis; Histocompatibility Antigens Class I; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Inflammation; Mice, Inbred C57BL; Neoplasms; Peptides; Protein Isoforms; Pyrroles; RNA Splicing; Sulfonamides; T-Lymphocytes | 2021 |
Targeting Pyruvate Kinase M2 Phosphorylation Reverses Aggressive Cancer Phenotypes.
Topics: Active Transport, Cell Nucleus; Animals; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Collagen; Cyclic N-Oxides; Drug Combinations; Genome, Human; Humans; Indolizines; Laminin; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Neoplasms; Oxidation-Reduction; Phenotype; Phosphorylation; Protein Isoforms; Proteoglycans; Proteomics; Pyridazines; Pyridinium Compounds; Pyrroles; Pyruvate Kinase; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Triple Negative Breast Neoplasms | 2021 |
Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.
Topics: Animals; Chlorocebus aethiops; Computer Simulation; COVID-19; COVID-19 Drug Treatment; Humans; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor Cross-Talk; SARS-CoV-2; Vero Cells; Virus Internalization | 2021 |
Singlet Oxygen-Responsive Polymeric Nanomedicine for Light-Controlled Drug Release and Image-Guided Photodynamic-Chemo Combination Therapy.
Topics: Acrylates; Animals; Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyethylene Glycols; Pyrroles; Singlet Oxygen | 2021 |
Increased incidence of gastrointestinal toxicity in canine cancer patients treated with concurrent abdominal radiation therapy and toceranib phosphate.
Topics: Abdomen; Animals; Dog Diseases; Dogs; Humans; Incidence; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies | 2022 |
Fluorescence/photoacoustic imaging-guided nanomaterials for highly efficient cancer theragnostic agent.
Topics: Animals; Cell Line, Tumor; Chitosan; Fluorescence; Humans; Nanocomposites; Neoplasms; Optical Imaging; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2021 |
Dihydropyrazole and dihydropyrrole structures based design of Kif15 inhibitors as novel therapeutic agents for cancer.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinesins; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyrazoles; Pyrroles; Quantitative Structure-Activity Relationship | 2017 |
Tyrosine kinase-targeting drugs-associated heart failure.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Case-Control Studies; Cetuximab; Cohort Studies; Heart Failure; Humans; Incidence; Indoles; Israel; Middle Aged; Neoplasms; Odds Ratio; Panitumumab; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sunitinib; Trastuzumab | 2017 |
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature.
Topics: Animals; Antineoplastic Agents; B7 Antigens; Benzodiazepines; Blood Vessels; Cell Line, Tumor; Endothelium, Vascular; Female; Humans; Immunoconjugates; Male; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Molecular Targeted Therapy; Neoplasms; Oligopeptides; Pyrroles; Rabbits | 2017 |
Ortho group activation of a bromopyrrole ester in Suzuki-Miyaura cross-coupling reactions: Application to the synthesis of new microtubule depolymerizing agents with potent cytotoxic activities.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrroles; Rats | 2017 |
Molecular docking studies of 3-bromopyruvate and its derivatives to metabolic regulatory enzymes: Implication in designing of novel anticancer therapeutic strategies.
Topics: Antineoplastic Agents; Citric Acid Cycle; Computer Simulation; Enzyme Inhibitors; Glycolysis; Humans; Ligands; Molecular Docking Simulation; Neoplasms; Propionates; Pyrroles; Pyruvates; Succinate Dehydrogenase | 2017 |
AKT Inhibition in Solid Tumors With AKT1 Mutations.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Diarrhea; Disease-Free Survival; DNA, Neoplasm; Drug Eruptions; Exanthema; Female; Humans; Hyperglycemia; Loss of Heterozygosity; Male; Middle Aged; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Signal Transduction | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
DNA-assisted upconversion nanoplatform for imaging-guided synergistic therapy and laser-switchable drug detoxification.
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; DNA; Female; HEK293 Cells; HeLa Cells; Humans; Hyperthermia, Induced; Luminescent Agents; Lutetium; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Polymers; Pyrroles; Sodium Fluoride | 2017 |
A pyrrole-based natural small molecule mitigates HSP90 expression in MDA-MB-231 cells and inhibits tumor angiogenesis in mice by inactivating HSF-1.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cornea; Down-Regulation; Female; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Mice; Mitogen-Activated Protein Kinase 3; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Plant Leaves; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Tinospora; Transplantation, Heterologous | 2017 |
Highly absorbing multispectral near-infrared polymer nanoparticles from one conjugated backbone for photoacoustic imaging and photothermal therapy.
Topics: Animals; Female; HeLa Cells; Humans; Hyperthermia, Induced; Infrared Rays; Ketones; MCF-7 Cells; Mice, Inbred ICR; Nanoparticles; Neoplasms; Optical Imaging; Photoacoustic Techniques; Phototherapy; Pyrroles; Theranostic Nanomedicine; Thiophenes | 2017 |
Diketopyrrolopyrrole-Based Photosensitizers Conjugated with Chemotherapeutic Agents for Multimodal Tumor Therapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles | 2017 |
Synthesis of Size-Tunable Hollow Polypyrrole Nanostructures and Their Assembly into Folate-Targeting and pH-Responsive Anticancer Drug-Delivery Agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; MicroRNAs; Nanostructures; Neoplasms; Optical Imaging; Photoelectron Spectroscopy; Polyethylene Glycols; Polymers; Pyrroles; Spectroscopy, Fourier Transform Infrared; Tissue Distribution; Titanium; Transplantation, Heterologous | 2017 |
Facile Preparation of Doxorubicin-Loaded and Folic Acid-Conjugated Carbon Nanotubes@Poly(N-vinyl pyrrole) for Targeted Synergistic Chemo-Photothermal Cancer Treatment.
Topics: Antibiotics, Antineoplastic; Doxorubicin; Drug Carriers; Drug Delivery Systems; Folic Acid; HeLa Cells; Humans; Hyperthermia, Induced; Nanotubes, Carbon; Neoplasms; Phototherapy; Polyvinyls; Pyrroles | 2017 |
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dimerization; Female; Humans; Immunoconjugates; Mice; Models, Molecular; Neoplasms; Pyrroles; Receptor, ErbB-2; Sialic Acid Binding Ig-like Lectin 2 | 2017 |
Pyrrolidinyl PNA polypyrrole/silver nanofoam electrode as a novel label-free electrochemical miRNA-21 biosensor.
Topics: Biosensing Techniques; Dielectric Spectroscopy; Electrochemical Techniques; Gold; Humans; Limit of Detection; MicroRNAs; Neoplasms; Nucleic Acid Hybridization; Polymers; Pyrroles; Pyrrolidines; Silver | 2018 |
Photo-based PDT/PTT dual model killing and imaging of cancer cells using phycocyanin-polypyrrole nanoparticles.
Topics: Cell Line; Cell Line, Tumor; Chemistry, Pharmaceutical; HEK293 Cells; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Phycocyanin; Polymers; Pyrroles; Reactive Oxygen Species; Serum Albumin, Bovine | 2018 |
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Female; Indoles; Male; Mast Cells; Neoplasms; Pyrroles; Retrospective Studies; Treatment Outcome | 2018 |
Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease.
Topics: Animals; Binding Sites; c-Mer Tyrosine Kinase; Cell Line, Tumor; Cell Proliferation; Fluorescent Dyes; Macrophages; Mice; Microscopy, Confocal; Molecular Docking Simulation; Neoplasm Metastasis; Neoplasms; Protein Structure, Tertiary; Pyrimidines; Pyrroles; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectroscopy, Near-Infrared; Structure-Activity Relationship | 2017 |
Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs.
Topics: Animals; Autoantibodies; Dog Diseases; Dogs; Female; Hypothalamus; Hypothyroidism; Indoles; Male; Neoplasms; Pituitary Gland; Prospective Studies; Pyrroles; Thyroglobulin; Thyroid Gland; Thyrotropin; Thyroxine; Triiodothyronine | 2018 |
pH Switchable Nanoassembly for Imaging a Broad Range of Malignant Tumors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Drug Screening Assays, Antitumor; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Ketones; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Neoplasms, Experimental; Pyrroles; Thiophenes; Tumor Microenvironment | 2017 |
Latent Warheads for Targeted Cancer Therapy: Design and Synthesis of pro-Pyrrolobenzodiazepines and Conjugates.
Topics: Antineoplastic Agents; Benzodiazepines; Chemistry Techniques, Synthetic; Drug Design; Humans; KB Cells; Molecular Targeted Therapy; Neoplasms; Prodrugs; Pyrroles | 2017 |
Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dasatinib; Denmark; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Pyrroles; Retrospective Studies; Sunitinib | 2018 |
Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
Topics: Animals; Antibodies; Benzodiazepines; Cell Line, Tumor; Drug Liberation; Humans; Immunoconjugates; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Pyrroles; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Tumor-Targeting Nanoparticles of Small-Molecule Diketopyrrolopyrrole Derivative for Photothermal Therapy.
Topics: Animals; Ketones; Lasers; Mice; Nanoparticles; Neoplasms; Phototherapy; Pyrroles | 2018 |
Restoration of conformation of mutant p53.
Topics: Alkylation; Aminoquinolines; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Ellipticines; Humans; Mutation; Neoplasms; Protein Binding; Protein Interaction Domains and Motifs; Pyrazoles; Pyrroles; Quinuclidines; Structure-Activity Relationship; Thiosemicarbazones; Tumor Suppressor Protein p53 | 2018 |
Targeting Polo-like Kinase 1 by a Novel Pyrrole-Imidazole Polyamide-Hoechst Conjugate Suppresses Tumor Growth
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Female; Fluorescent Dyes; HeLa Cells; Humans; Imidazoles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Nylons; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrroles; Xenograft Model Antitumor Assays | 2018 |
Functionalized poly(pyrrole-3-carboxylic acid) nanoneedles for dual-imaging guided PDT/PTT combination therapy.
Topics: Animals; Carboxylic Acids; Combined Modality Therapy; Female; HeLa Cells; Humans; Hyperthermia, Induced; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasms; Optical Imaging; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Polymers; Pyrroles; RAW 264.7 Cells; Theranostic Nanomedicine; Thermography | 2018 |
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Incidence; Indoles; Ipilimumab; Jaw Diseases; Male; Middle Aged; Neoplasms; Osteonecrosis; Pamidronate; Pyrroles; Retrospective Studies; Sunitinib; Zoledronic Acid | 2018 |
Hydrophobic structure of hairpin ten-ring pyrrole-imidazole polyamides enhances tumor tissue accumulation/retention in vivo.
Topics: Animals; Cell Line, Tumor; Cell Nucleus; Female; Fluoresceins; Fluorescence; Fluorescent Dyes; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Mice, Inbred BALB C; Molecular Structure; Neoplasms; Nylons; Pyrroles; Tissue Distribution | 2018 |
Quinonoid compounds via reactions of lawsone and 2-aminonaphthoquinone with α-bromonitroalkenes and nitroallylic acetates: Structural diversity by C-ring modification and cytotoxic evaluation against cancer cells.
Topics: Acetates; Alkenes; Amination; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Furans; Halogenation; Humans; Models, Molecular; Naphthoquinones; Neoplasms; Pyrroles; Quinones; Structure-Activity Relationship | 2018 |
A theranostic nanocomposite system based on iron oxide-drug nanocages for targeted magnetic field responsive chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Proliferation; Drug Delivery Systems; Ferric Compounds; HeLa Cells; Humans; Magnetic Fields; MCF-7 Cells; Nanocomposites; Neoplasms; Pyrroles; Quinones; Theranostic Nanomedicine | 2018 |
pH/NIR-Responsive Polypyrrole-Functionalized Fibrous Localized Drug-Delivery Platform for Synergistic Cancer Therapy.
Topics: Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Infrared Rays; Neoplasms; Polymers; Pyrroles | 2018 |
NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Drug Liberation; Fluorescent Dyes; Heterografts; Humans; Hypothermia, Induced; Infrared Rays; Lasers; Mice; Nanocapsules; Neoplasms; Photoacoustic Techniques; Photochemotherapy; Polyhydroxyethyl Methacrylate; Polymers; Prodrugs; Pyrroles; Theranostic Nanomedicine | 2018 |
Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship; Urea | 2018 |
Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diphtheria Toxin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gene Knockout Techniques; Humans; Lymphocyte Depletion; Macrophages; Male; Mice; Mice, Transgenic; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Cell Culture; Purines; Pyrroles; Quinazolinones; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2018 |
A retrospective study of proteinuria in dogs receiving toceranib phosphate.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dog Diseases; Dogs; Female; Glucocorticoids; Incidence; Indoles; Male; Neoplasms; Proteinuria; Pyrroles; Retrospective Studies | 2018 |
Purin-6-one and pyrrolo[2,3-d]pyrimidin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Neoplasms; Purinones; Pyrimidinones; Pyrroles | 2018 |
Antibody-Drug Conjugates with Pyrrole-Based KSP Inhibitors as the Payload Class.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Discovery; Humans; Immunoconjugates; Kinesins; Neoplasms; Pyrroles | 2018 |
Microwave-assisted ultrafast fabrication of high-performance polypyrrole nanoparticles for photothermal therapy of tumors in vivo.
Topics: Animals; Cell Line, Tumor; Cell Survival; Hyperthermia, Induced; Lasers; Mice; Microscopy, Electron, Transmission; Microwaves; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles | 2018 |
Chemoresistance of cancer floating cells is independent of their ability to form 3D structures: Implications for anticancer drug screening.
Topics: Antibodies; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Adhesion; Cell Culture Techniques; Cell Survival; Colchicine; Culture Media, Serum-Free; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Indoles; Male; MCF-7 Cells; Neoplasms; PC-3 Cells; Phenotype; Pyrroles; Spheroids, Cellular | 2019 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; MCF-7 Cells; Neoplasms; Pyridines; Pyrroles; Structure-Activity Relationship | 2018 |
Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrroles; Triazines; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells.
Topics: Acetylation; AMP-Activated Protein Kinases; Apoptosis; Autophagosomes; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Cycle; Cell Proliferation; Enzyme Activation; HCT116 Cells; HeLa Cells; Histones; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Pyrroles; Quinoxalines; Reactive Oxygen Species; Signal Transduction; Sirtuins | 2018 |
Mutagenic assessment of chemotherapy and Smac mimetic drugs in cells with defective DNA damage response pathways.
Topics: Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cyclohexanes; DNA Damage; DNA End-Joining Repair; Drug Delivery Systems; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Mutagenesis; Neoplasm Proteins; Neoplasms; Pyrroles | 2018 |
Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Mice, Nude; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrimidines; Pyrroles; Stereoisomerism; Tubulin; Tubulin Modulators | 2018 |
Fe
Topics: Animals; Cell Line; Delayed-Action Preparations; Doxorubicin; Hydrogels; Infrared Rays; Mice; Neoplasms; Polymers; Pyrroles | 2018 |
Maritoclax Enhances TRAIL-Induced Apoptosis via CHOP-Mediated Upregulation of DR5 and miR-708-Mediated Downregulation of cFLIP.
Topics: A549 Cells; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Up-Regulation | 2018 |
Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach.
Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Body Weight; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Inhibitory Concentration 50; Injections, Intravenous; Mice; Nanoparticles; Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Xenograft Model Antitumor Assays | 2019 |
Pyrrolopyrrole aza-BODIPY near-infrared photosensitizer for dual-mode imaging-guided photothermal cancer therapy.
Topics: Animals; Boron Compounds; HeLa Cells; Humans; Infrared Rays; Mice; Microscopy, Confocal; Neoplasms; Optical Imaging; Photoacoustic Techniques; Photosensitizing Agents; Phototherapy; Pyrroles; Transplantation, Heterologous | 2019 |
Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.
Topics: Acetamides; Afatinib; Animals; Cell Membrane Permeability; Clotrimazole; Colon; Cystic Fibrosis Transmembrane Conductance Regulator; Diarrhea; Disease Models, Animal; Epithelial Cells; ErbB Receptors; Female; Humans; Intestinal Mucosa; Neoplasms; Oxazines; Potassium Channel Blockers; Potassium Channels; Protein Kinase Inhibitors; Pyrimidinones; Pyrroles; Rats; Trityl Compounds | 2019 |
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
Topics: Animals; Antibodies; Arginase; Breast Neoplasms; Cell Line, Tumor; Cytokines; Disease Models, Animal; Female; Immunoconjugates; Immunotherapy; Immunotoxins; Macrophages; Mice; Mice, Nude; Monocytes; Neoplasms; Neutrophils; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Synthesis and evaluation of novel 7
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2019 |
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphorylation; Piperazines; Pyrroles; Random Allocation; Rats; Receptors, Fibroblast Growth Factor; Thiophenes; Xenograft Model Antitumor Assays | 2019 |
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Engineered Cell-Assisted Photoactive Nanoparticle Delivery for Image-Guided Synergistic Photodynamic/Photothermal Therapy of Cancer.
Topics: Animals; Cell Line, Tumor; Female; Humans; Ketones; Lasers; Mice; Mice, Inbred BALB C; Mice, Nude; Monocytes; Nanoparticles; Neoplasms; Oligopeptides; Peptides, Cyclic; Photochemotherapy; Photosensitizing Agents; Phototherapy; Pyrroles; Quantum Theory; Singlet Oxygen; Transplantation, Heterologous | 2019 |
PRMT1 loss sensitizes cells to PRMT5 inhibition.
Topics: A549 Cells; Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Ethylenediamines; Gene Deletion; Humans; Isoquinolines; MCF-7 Cells; Mice, Knockout; Neoplasms; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles; Repressor Proteins; Signal Transduction | 2019 |
Development of a p38α-selective radioactive probe for qualitative diagnosis of cancer using SPECT.
Topics: Animals; Biological Transport; Cell Line, Tumor; Humans; Male; Mice; Mitogen-Activated Protein Kinase 14; Neoplasms; Phosphorylation; Pyrroles; Tissue Distribution; Tomography, Emission-Computed, Single-Photon | 2019 |
TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.
Topics: Animals; Cell Line, Tumor; Humans; Male; Mice; Mice, SCID; NEDD8 Protein; Neoplasms; Pyrimidines; Pyrroles | 2019 |
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Artemisinins; Crystallography, X-Ray; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrroles | 2020 |
Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
Topics: Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Methylation; Molecular Docking Simulation; Neoplasms; Protein Binding; Protein-Arginine N-Methyltransferases; Pyrimidines; Pyrroles; Quinolines; Structure-Activity Relationship; Triazoles | 2019 |
Synthesis and antiproliferative activity of 2,5-bis(3'-indolyl)pyrroles, analogues of the marine alkaloid nortopsentin.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasms; Pyrroles; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Thienopyrrole-expanded BODIPY as a potential NIR photosensitizer for photodynamic therapy.
Topics: Boron Compounds; Cell Survival; HeLa Cells; Humans; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles | 2013 |
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Humans; Male; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, TIE-2; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2013 |
Update in rheumatology: evidence published in 2012.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Antiviral Agents; Arthritis; Arthritis, Gouty; Arthritis, Rheumatoid; Autoimmune Diseases; Bacterial Infections; Calcitonin; Colchicine; Cryoglobulinemia; Death, Sudden, Cardiac; Drug Resistance, Viral; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Hand Joints; Hepatitis C, Chronic; Humans; Hyperuricemia; Immunologic Factors; Janus Kinase 3; Male; Myocardial Infarction; Neoplasms; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Practice Guidelines as Topic; Protein Precursors; Pyrimidines; Pyrroles; Registries; Tumor Necrosis Factor-alpha | 2013 |
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Proliferation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mammary Glands, Human; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Stability; Pyrroles; Quinolones; Transforming Growth Factor beta2; Ubiquitination; Up-Regulation | 2013 |
[Advantages of volume perfusion CT for evaluating the response of solid tumors to treatment with sunitinib].
Topics: Aged; Female; Humans; Imaging, Three-Dimensional; Indoles; Male; Middle Aged; Neoplasms; Perfusion Imaging; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Iron oxide @ polypyrrole nanoparticles as a multifunctional drug carrier for remotely controlled cancer therapy with synergistic antitumor effect.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Drug Carriers; Female; Ferric Compounds; Humans; Magnetic Resonance Imaging; Magnetics; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanocomposites; Nanoparticles; Nanotechnology; Neoplasm Transplantation; Neoplasms; Polyethylene Glycols; Polymers; Pyrroles | 2013 |
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; Humans; Mitosis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles | 2013 |
Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance.
Topics: Apoptosis; Cell Survival; Drug Resistance, Neoplasm; HeLa Cells; Humans; Indoles; Lysosomes; MCF-7 Cells; Neoplasms; Pyrroles; Sphingomyelin Phosphodiesterase; Sunitinib | 2013 |
Synthesis and evaluation of pyrrole polyamide-2'-deoxyguanosine 5'-phosphate hybrid.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxyguanine Nucleotides; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, Animal; Mice; Molecular Structure; Neoplasms; Nylons; Pyrroles | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.
Topics: Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Indoles; Male; Neoplasms; Pyrroles; Vascular Endothelial Growth Factor A | 2013 |
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP3A; Female; Humans; Indoles; Male; Midazolam; Middle Aged; Neoplasms; Phenotype; Prospective Studies; Pyrroles; Sunitinib | 2014 |
Multifunctional polypyrrole@Fe(3)O(4) nanoparticles for dual-modal imaging and in vivo photothermal cancer therapy.
Topics: Animals; Ferric Compounds; HeLa Cells; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Mice; Mice, Nude; Multimodal Imaging; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Spectrophotometry, Ultraviolet; Temperature | 2014 |
Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Topics: Aged; Antineoplastic Agents; Benzamides; Body Weight; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Female; Gastric Acid; Half-Life; Histamine H2 Antagonists; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasms; Outpatients; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Tandem Mass Spectrometry | 2014 |
Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells.
Topics: Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation, Developmental; Hedgehog Proteins; Humans; Indoles; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Mice; Multipotent Stem Cells; Neoplasms; Nuclear Proteins; Oxindoles; Propionates; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2014 |
Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Therapy; Humans; Indoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oncolytic Virotherapy; Oncolytic Viruses; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Vaccinia virus; Vascular Endothelial Growth Factor A | 2014 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
Methods for adjusting for bias due to crossover in oncology trials.
Topics: Antineoplastic Agents; Bias; Cost-Benefit Analysis; Cross-Over Studies; Humans; Indoles; Kaplan-Meier Estimate; Models, Statistical; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2014 |
In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Contrast Media; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Female; Humans; Indoles; Magnetic Resonance Imaging; Mice, Inbred C3H; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxidation-Reduction; Oxygen; Pyrroles; Pyruvic Acid; Sunitinib; Xenograft Model Antitumor Assays | 2014 |
An electroactive biotin-doped polypyrrole substrate that immobilizes and releases EpCAM-positive cancer cells.
Topics: Antigens, Neoplasm; Biotin; Cell Adhesion Molecules; Electric Conductivity; Epithelial Cell Adhesion Molecule; Humans; Neoplasms; Polymers; Pyrroles; Streptavidin; Surface Properties; Tumor Cells, Cultured | 2014 |
Polypyrrole-coated chainlike gold nanoparticle architectures with the 808 nm photothermal transduction efficiency up to 70%.
Topics: Animals; Cell Line, Tumor; Gold; Hot Temperature; Humans; Hyperthermia, Induced; Metal Nanoparticles; Mice; Neoplasms; Phototherapy; Polymers; Pyrroles | 2014 |
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Encapsulating tantalum oxide into polypyrrole nanoparticles for X-ray CT/photoacoustic bimodal imaging-guided photothermal ablation of cancer.
Topics: Animals; Contrast Media; Female; HeLa Cells; Humans; Hyperthermia, Induced; Infrared Rays; Injections, Intralesional; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxides; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Tantalum; Tomography, X-Ray Computed | 2014 |
Pyrrole alkaloids with potential cancer chemopreventive activity isolated from a goji berry-contaminated commercial sample of African mango.
Topics: Alkaloids; Animals; Drug Contamination; Fruit; Lycium; Mangifera; Neoplasms; Plant Extracts; Pyrroles; Rats | 2014 |
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Humans; Hypertension; Incidence; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Middle Aged; Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sunitinib | 2014 |
Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Emulsions; Endothelium, Vascular; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Neovascularization, Pathologic; Pharmaceutical Vehicles; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Colchicine; Drug Screening Assays, Antitumor; Guanidines; Hedgehog Proteins; Humans; M Phase Cell Cycle Checkpoints; Mice; Molecular Docking Simulation; Neoplasms; Polymerization; Protein Binding; Pyrroles; Signal Transduction; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2014 |
Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
Topics: Antineoplastic Agents; Binding Sites; ErbB Receptors; Humans; Molecular Docking Simulation; Neoplasms; Protein Binding; Pyrimidines; Pyrroles; Quantitative Structure-Activity Relationship; User-Computer Interface | 2015 |
An integrated multifunctional platform based on biotin-doped conducting polymer nanowires for cell capture, release, and electrochemical sensing.
Topics: Antibodies, Immobilized; Biosensing Techniques; Biotin; Cell Line, Tumor; Cell Separation; Electrochemical Techniques; Equipment Design; Humans; Immunohistochemistry; Limit of Detection; Nanowires; Neoplasms; Polymers; Pyrroles | 2014 |
Synthesis, hydrolytic DNA-cleaving activities and cytotoxicities of EDTA analogue-tethered pyrrole-polyamide dimer-based Ce(IV) complexes.
Topics: Antineoplastic Agents; Cell Proliferation; Cerium; Coordination Complexes; DNA Cleavage; DNA, Superhelical; Drug Design; Drug Screening Assays, Antitumor; Edetic Acid; Flow Cytometry; Humans; Molecular Structure; Neoplasms; Nylons; Organometallic Compounds; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Mice, SCID; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Assessing metastasis risk after pre-operative anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Pyrroles | 2014 |
Synthesis of Novel Hybrids Inspired from Bromopyrrole Alkaloids Inhibiting MMP-2 and -12 as Antineoplastic Agents.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; MCF-7 Cells; Neoplasms; Pyrroles; Semicarbazides; Structure-Activity Relationship | 2015 |
HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents.
Topics: Acrolein; Antineoplastic Agents; Antioxidant Response Elements; Cell Line, Tumor; Cytotoxins; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-pim-1; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction | 2014 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Dithiocarbamate/piperazine bridged pyrrolobenzodiazepines as DNA-minor groove binders: synthesis, DNA-binding affinity and cytotoxic activity.
Topics: Antineoplastic Agents; Benzodiazepines; Binding Sites; Cell Line, Tumor; Cell Survival; DNA; Humans; Models, Molecular; Neoplasms; Nucleic Acid Conformation; Piperazines; Pyrroles; Structure-Activity Relationship; Thiocarbamates | 2015 |
Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Drug Design; ErbB Receptors; Humans; MCF-7 Cells; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship | 2015 |
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden | 2015 |
Dual Functioning Thieno-Pyrrole Fused BODIPY Dyes for NIR Optical Imaging and Photodynamic Therapy: Singlet Oxygen Generation without Heavy Halogen Atom Assistance.
Topics: Animals; Apoptosis; Boron Compounds; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Fluorescent Dyes; Halogens; Heterocyclic Compounds, 4 or More Rings; Humans; Lasers; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Conformation; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles; Quantum Theory; Singlet Oxygen; Spectroscopy, Near-Infrared; Structure-Activity Relationship; Transplantation, Heterologous | 2015 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, nortopsentin analogues with antiproliferative activity.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; G2 Phase; Halogenation; Humans; Imidazoles; Indoles; Membrane Potential, Mitochondrial; Methylation; Mitochondria; Molecular Structure; Neoplasms; Pyridines; Pyrroles; Resting Phase, Cell Cycle; Thiazoles | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Indoles; Mice, Nude; Nanoparticles; Neoplasms; Peptides, Cyclic; Porosity; Positron-Emission Tomography; Pyrroles; Silicon Dioxide; Sunitinib | 2015 |
Microwave-Assisted Synthesis of Novel Pyrazolo[3,4-g][1,8]naphthyridin-5-amine with Potential Antifungal and Antitumor Activity.
Topics: Antifungal Agents; Antineoplastic Agents; Candida albicans; Cell Line, Tumor; Chlorides; Cryptococcus neoformans; Humans; Ketones; Microbial Sensitivity Tests; Microwaves; Naphthyridines; Neoplasms; Pyrroles; Zinc Compounds | 2015 |
CCR 20th Anniversary Commentary: Determining a Pharmacokinetic/Pharmacodynamic Relationship for Sunitinib—A Look Back.
Topics: Anniversaries and Special Events; History, 21st Century; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2015 |
A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models.
Topics: Animals; Biological Assay; Cell Line, Tumor; Cell Movement; Endoplasmic Reticulum; Fibroblasts; Humans; Ligands; Models, Biological; Models, Molecular; Neoplasms; Pyrroles; Receptors, G-Protein-Coupled; Signal Transduction; Xenopus | 2015 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Drug Tolerance; Esterases; Female; Humans; Hydrolysis; Indoles; Mice; Neoplasms; Phosphorylation; Prodrugs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; STAT3 Transcription Factor; Sunitinib; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Targeting Mutant AKT in Cancer.
Topics: Clinical Trials, Phase I as Topic; Drug Synergism; Estradiol; Fulvestrant; Humans; Mutation; Neoplasms; Neoplastic Cells, Circulating; Precision Medicine; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Drug therapy: Preclinical oncology - reporting transparency needed.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2016 |
Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridines; Pyrroles; Structure-Activity Relationship; Triazoles | 2016 |
Retrospective evaluation of toceranib phosphate (Palladia®) toxicity in cats.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Azotemia; Cat Diseases; Cats; Female; Gastrointestinal Tract; Indoles; Male; Neoplasms; Neutropenia; Pyrroles; Retrospective Studies; Thrombocytopenia | 2017 |
Bromo-Substituted Diketopyrrolopyrrole Derivative with Specific Targeting and High Efficiency for Photodynamic Therapy.
Topics: Hyaluronic Acid; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyrroles | 2016 |
Evaluation on the inhibition of pyrrol-2-yl ethanone derivatives to lactate dehydrogenase and anticancer activities.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Hep G2 Cells; Humans; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Neoplasms; Pyrroles; Pyruvic Acid | 2016 |
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Case-Control Studies; Cohort Studies; Dog Diseases; Dogs; Hypertension; Indoles; Neoplasms; Prospective Studies; Protein-Tyrosine Kinases; Proteinuria; Pyrroles | 2016 |
Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia.
Topics: Animals; Benzylamines; Biomarkers; Cachexia; Chemokine CXCL12; Cyclams; Cytokines; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Indoles; Male; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Pyrroles; Rats; Receptors, CXCR4; Signal Transduction; Sunitinib | 2016 |
High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors.
Topics: Amides; Antineoplastic Agents; High-Throughput Screening Assays; Humans; Mitogen-Activated Protein Kinase 14; Mitogen-Activated Protein Kinase 7; Molecular Structure; Neoplasms; Protein Binding; Protein Kinase Inhibitors; Pyrroles; Structure-Activity Relationship | 2016 |
Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates.
Topics: Animals; Antibodies, Monoclonal, Humanized; Benzodiazepines; Female; Immunoconjugates; Mice; Mice, SCID; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays | 2016 |
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment | 2017 |
Nucleophilic Aromatic Substitution on Pentafluorophenyl-Substituted Dipyrranes and Tetrapyrroles as a Route to Multifunctionalized Chromophores for Potential Application in Photodynamic Therapy.
Topics: Amines; Benzaldehydes; Boron Compounds; Cell Line, Tumor; Chemistry Techniques, Synthetic; Halogenation; Humans; Models, Molecular; Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Pyrroles; Tetrapyrroles | 2016 |
Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism.
Topics: Angiogenesis Inhibitors; Animals; Female; Humans; Indoles; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Synthesis and Anticancer Activity of 3-(Substituted Aroyl)-4-(3,4,5-trimethoxyphenyl)-1H-pyrrole Derivatives.
Topics: Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship | 2017 |
Quantitative Chemical Proteomic Profiling of Ubiquitin Specific Proteases in Intact Cancer Cells.
Topics: Alkynes; Cell Line, Tumor; Humans; Molecular Probe Techniques; Molecular Probes; Neoplasms; Proteomics; Pyrroles; Small Molecule Libraries; Ubiquitin-Specific Proteases | 2016 |
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Delayed-Action Preparations; Drug Administration Schedule; Drug Approval; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Models, Animal; Models, Biological; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats, Sprague-Dawley; Therapeutic Equivalency; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Dual modulation of MCL-1 and mTOR determines the response to sunitinib.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Stability; Glycogen Synthase Kinase 3 beta; Humans; Indoles; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred NOD; Mice, Nude; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Robust Colloidal Nanoparticles of Pyrrolopyrrole Cyanine J-Aggregates with Bright Near-Infrared Fluorescence in Aqueous Media: From Spectral Tailoring to Bioimaging Applications.
Topics: Animals; Cell Line, Tumor; Cell Survival; Colloids; Fluorescent Dyes; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Pyrroles; Sonication; Spectrophotometry; Spectroscopy, Near-Infrared; Transplantation, Heterologous; Water | 2017 |
Targeted drug delivery of Sunitinib Malate to tumor blood vessels by cRGD-chiotosan-gold nanoparticles.
Topics: Cell Survival; Cells, Cultured; Chitosan; Drug Carriers; Drug Liberation; Gold; Humans; Indoles; Nanoparticles; Neoplasms; Particle Size; Peptides, Cyclic; Pyrroles; Sunitinib; Surface Properties | 2017 |
Synthesis and Evaluation of Cytotoxic Activity of Some Pyrroles and Fused Pyrroles.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Neoplasms; Pyrroles; Signal Transduction | 2017 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Topics: Female; Humans; Hypertension; Indoles; Male; Neoplasms; Neovascularization, Pathologic; Nitric Oxide Donors; Pyrroles; Sunitinib | 2015 |
Pyrrolo[3',2':6,7]cyclohepta[1,2-b]pyridines with potent photo-antiproliferative activity.
Topics: Antineoplastic Agents; Antioxidants; Blotting, Western; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Light; Neoplasms; Photosensitizing Agents; Pyridines; Pyrroles; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers.
Topics: Animals; Antibodies; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disulfides; Humans; Immunoconjugates; Mice; Neoplasms; Pyrroles; Xenograft Model Antitumor Assays | 2017 |
Multifunctional biocompatible chitosan-polypyrrole nanocomposites as novel agents for photoacoustic imaging-guided photothermal ablation of cancer.
Topics: Animals; Cell Line, Tumor; Chitosan; Disease Models, Animal; Female; Humans; Hyperthermia, Induced; Mice; Nanocomposites; Neoplasms; Photoacoustic Techniques; Phototherapy; Polymers; Pyrroles; Xenograft Model Antitumor Assays | 2017 |
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness | 2017 |
Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Duocarmycins; Glucuronates; Glucuronic Acid; Humans; Indoles; Inhibitory Concentration 50; Neoplasms; Prodrugs; Pyrroles | 2008 |
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory can
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Enzyme Inhibitors; Humans; Kinesins; Neoplasms; Piperidines; Pyrroles; Taxoids | 2008 |
Bcl-2 family members as molecular targets in cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzopyrans; BH3 Interacting Domain Death Agonist Protein; Biological Products; Genes, bcl-2; Gossypol; Humans; Indoles; Neoplasms; Nitriles; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Pyrroles | 2008 |
Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
Topics: Angiogenesis Inhibitors; Female; Humans; Hypothyroidism; Indoles; Male; Neoplasms; Pyrroles; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2008 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Cost effectiveness of sunitinib.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Data Interpretation, Statistical; Drug Costs; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
Topics: Antineoplastic Agents; beta-Galactosidase; Cell Line, Tumor; Duocarmycins; Glycosides; Humans; Indoles; Inhibitory Concentration 50; Neoplasms; Prodrugs; Pyrroles; Stereoisomerism | 2008 |
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.
Topics: Antineoplastic Agents; Azepines; Checkpoint Kinase 1; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Electrons; Humans; Inhibitory Concentration 50; Models, Chemical; Molecular Structure; Neoplasms; Protein Kinases; Pyrroles; Structure-Activity Relationship; Thiophenes | 2009 |
Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
Topics: Antibodies; beta-Galactosidase; Chromatography, High Pressure Liquid; Duocarmycins; Glycosides; Indoles; Magnetic Resonance Spectroscopy; Neoplasms; Prodrugs; Pyrroles; Spectrometry, Mass, Electrospray Ionization | 2009 |
The TNT study, women and cancer.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
Statin therapy as the fundamental therapy for cardiovascular prevention: be careful.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Humans; Indoles; Male; Neoplasms; Prospective Studies; Pyrroles; Sunitinib | 2009 |
Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Inhibitory Concentration 50; Methotrexate; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Sunitinib; Time Factors; Topotecan; Transfection; Up-Regulation; Vincristine | 2009 |
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Humans; Indoles; Mice; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indoles; Linear Models; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sunitinib | 2009 |
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta-Galactosidase; Cell Line, Tumor; Drug Design; Duocarmycins; Glycosides; Humans; Indoles; Neoplasms; Prodrugs; Pyrroles; Stereoisomerism | 2009 |
Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclooxygenase 2 Inhibitors; Humans; Inflammation; Neoplasms; Pain; Pyrroles; Sulfonamides | 2009 |
Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cytokines; Dermatitis, Contact; Female; Flow Cytometry; Histocytochemistry; Humans; Indoles; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Neoplasms; Picryl Chloride; Pyrroles; Specific Pathogen-Free Organisms; Sunitinib; T-Lymphocytes | 2010 |
Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzazepines; Carbamates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Microtubules; Neoplasm Proteins; Neoplasms; Oxazepines; Pyrroles; Tubulin Modulators | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
In vitro and in vivo antineoplastic activity of a novel bromopyrrole and its potential mechanism of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Calcium; Caspase 3; Caspase 9; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Female; Flow Cytometry; HeLa Cells; Hemiterpenes; Hep G2 Cells; Humans; Lethal Dose 50; Male; Mice; Neoplasms; Porifera; Pyrroles; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Comparative analysis of DNA alkylation by conjugates between pyrrole-imidazole hairpin polyamides and chlorambucil or seco-CBI.
Topics: Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Chlorambucil; DNA; Humans; Imidazoles; Lymphocytes; Molecular Structure; Neoplasms; Nylons; Pyrroles | 2010 |
Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Gelatinases; Humans; Indoles; Kidney; Kidney Neoplasms; Lipocalins; Neoplasms; Neutrophils; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2010 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
The promise of biomarkers for personalized renal cancer care.
Topics: Biomarkers; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasms; Nervous System Neoplasms; Patients; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Control of leucocyte differentiation from embryonic stem cells upon vasculogenesis and confrontation with tumour tissue.
Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Biomarkers; Cell Differentiation; Cell Line; Embryonic Stem Cells; Indoles; Leukocytes; Lipopolysaccharides; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Monocytes; Neoplasms; Neovascularization, Physiologic; Pyrroles | 2010 |
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinases; E2F Transcription Factors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrazoles; Pyrroles; Skin; Transcriptional Activation; Xenograft Model Antitumor Assays | 2010 |
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Crystallography; Guanine Nucleotide Exchange Factors; Humans; Models, Molecular; Neoplasms; p21-Activated Kinases; Phosphorylation; Pyrazoles; Pyrroles; Rho Guanine Nucleotide Exchange Factors; Signal Transduction | 2010 |
Tyrosine kinase inhibitors and acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Humans; Indoles; Neoplasms; Pancreatitis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sunitinib | 2010 |
ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Humans; Immunosuppression Therapy; Mice; Mice, Nude; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pyrroles; Pyrrolidinones; Quinolines; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Close encounters of a novel kind: a multi-targeted cancer drug meets a metabolic sensor.
Topics: AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Animals; Humans; Indoles; Neoplasms; Pyrroles; Sunitinib | 2010 |
Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells.
Topics: Antineoplastic Agents; Cell Hypoxia; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Neoplasms; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib | 2010 |
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cricetinae; Cricetulus; Drug Delivery Systems; Female; Folic Acid Antagonists; Growth Inhibitors; HeLa Cells; Humans; Membrane Transport Proteins; Neoplasms; Proton-Coupled Folate Transporter; Purines; Pyrimidines; Pyrroles; Xenopus laevis | 2010 |
SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.
Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepinones; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Female; Humans; Mice; Neoplasms; Prodrugs; Pyrroles; Xenograft Model Antitumor Assays | 2010 |
Synthesis of 5,6-dihydropyrrolo[2,1-a]isoquinolines featuring an intramolecular radical-oxidative cyclization of polysubstituted pyrroles, and evaluation of their cytotoxic activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclization; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Models, Molecular; Neoplasms; Oxidation-Reduction; Pyrroles; Structure-Activity Relationship | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Design, synthesis and qualitative structure-activity evaluations of novel hexahydropyrano[3,2-c][1,2]diazepin-3(4H)-one and tetrahydropyrano[3,2-b]pyrrol-2(1H)-one derivatives as anticancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Neoplasms; Pyrans; Pyrroles; Structure-Activity Relationship | 2010 |
Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Neoplasms; Protein Binding; Pyrroles; Quinolones; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
The cancer-HIV/AIDS treatment conundrum.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Antagonism; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Neoplasms; Pyrroles; Risk Factors; Ritonavir; Sunitinib | 2010 |
Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis.
Topics: Adenosine Triphosphate; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indoles; Mitochondria; Neoplasms; Peptides; Platinum; Protein Structure, Tertiary; Protein Transport; Pyrroles | 2011 |
Circulating perivascular progenitors: a target of PDGFR inhibition.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Cell Count; Cell Differentiation; Cell Survival; Humans; Indoles; Mice; Neoplasms; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Stem Cells; Sunitinib | 2011 |
Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro.
Topics: Aerobiosis; Apoptosis; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Microtubules; Neoplasms; Oxazepines; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents | 2011 |
Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Humans; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Receptor, ErbB-2; Stomach Neoplasms; Triazines; Xenograft Model Antitumor Assays | 2011 |
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Hair Follicle; HCT116 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Xenograft Model Antitumor Assays | 2011 |
Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Endothelial Cells; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Piperidines; Pyrroles; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2011 |
Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro.
Topics: Amides; Blotting, Western; Cell Line, Tumor; Cell Movement; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin beta1; Magnetic Resonance Spectroscopy; Neoplasm Metastasis; Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Fast Atom Bombardment; Spectrophotometry, Infrared | 2011 |
Synthesis of aryl-substituted naphthalene-linked pyrrolobenzodiazepine conjugates as potential anticancer agents with apoptosis-inducing ability.
Topics: Antineoplastic Agents; Apoptosis; Benzodiazepines; Caspase 9; Cell Line, Tumor; Drug Design; Humans; Naphthalenes; Neoplasms; Pyrroles; Tumor Suppressor Protein p53 | 2011 |
Atorvastatin and clopidogrel interfere with photosensitization in vitro.
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cathepsin B; Cell Line; Clopidogrel; Heptanoic Acids; Humans; Light; Macrophages; Mice; Neoplasms; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Polylysine; Porphyrins; Pyrroles; Ticlopidine | 2011 |
A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Humans; Indoles; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish | 2011 |
Production of anticancer polyenes through precursor-directed biosynthesis.
Topics: Antineoplastic Agents; Fungi; HeLa Cells; Humans; Inhibitory Concentration 50; Neoplasms; Polyenes; Proline; Pyrones; Pyrroles | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; HCT116 Cells; HT29 Cells; Humans; Indoles; Kidney Neoplasms; Lysosomes; Mice; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2011 |
Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
Topics: Antineoplastic Agents; ErbB Receptors; HeLa Cells; Humans; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2011 |
Silencing p110β prevents rapid depletion of nuclear pAkt.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Class I Phosphatidylinositol 3-Kinases; Fibroblasts; Gene Silencing; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; RNA, Small Interfering; Tacrolimus Binding Proteins | 2011 |
Polypyrrole nanoparticles: a potential optical coherence tomography contrast agent for cancer imaging.
Topics: Contrast Media; Diagnostic Imaging; Humans; Medical Oncology; Models, Statistical; Nanoparticles; Neoplasms; Phantoms, Imaging; Polymers; Pyrroles; Scattering, Radiation; Spectrophotometry, Ultraviolet; Spectroscopy, Near-Infrared; Tomography, Optical Coherence | 2011 |
Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
Topics: Adenocarcinoma; Anal Gland Neoplasms; Anal Sacs; Animals; Antineoplastic Agents; Apocrine Glands; Bone Neoplasms; Carcinoma; Dog Diseases; Dogs; Female; Head and Neck Neoplasms; Indoles; Male; Neoplasms; Nose Neoplasms; Osteosarcoma; Pyrroles; Receptor Protein-Tyrosine Kinases; Skin Neoplasms; Thyroid Neoplasms | 2012 |
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Antineoplastic Agents; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Humans; Indoles; Neoplasms; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tandem Mass Spectrometry | 2012 |
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Topics: Antineoplastic Agents; Autophagy; bcl-X Protein; Cell Line, Tumor; ErbB Receptors; Humans; Indoles; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Antiangiogenic agents: fueling cancer's hypoxic roots.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Hypoxia; Humans; Indoles; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2012 |
Underestimating cardiac toxicity in cancer trials: lessons learned?
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Drug Labeling; Drug Monitoring; Heart Diseases; Humans; Indoles; Neoplasms; Pyrroles; Stroke Volume; Sunitinib; Ventricular Dysfunction, Left | 2012 |
The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses.
Topics: Antineoplastic Agents; Atorvastatin; Cell Cycle; Cell Line; Computational Biology; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrroles | 2012 |
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak.
Topics: Acenaphthenes; Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Inbred BALB C; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Peptide Fragments; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Polypyrrole nanoparticles for high-performance in vivo near-infrared photothermal cancer therapy.
Topics: Animals; Cell Line, Tumor; Cell Survival; Humans; Infrared Rays; Mice; Nanoparticles; Neoplasms; Phototherapy; Polymers; Pyrroles; Tissue Distribution | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
In vitro and in vivo near-infrared photothermal therapy of cancer using polypyrrole organic nanoparticles.
Topics: Animals; Cell Line, Tumor; Cell Survival; Female; HEK293 Cells; Humans; Infrared Rays; L-Lactate Dehydrogenase; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Phototherapy; Polymers; Polyvinyl Alcohol; Pyrroles; Transplantation, Heterologous | 2012 |
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Biotransformation; Cytochrome P-450 Enzyme System; Female; Hepatocytes; Humans; Indoles; Isoenzymes; Male; Microsomes, Liver; Middle Aged; Neoplasms; Oxidation-Reduction; Pyrroles; Receptor Protein-Tyrosine Kinases; Tissue Distribution | 2013 |
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
Topics: Acenaphthenes; Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitriles; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship | 2013 |
Pharmacokinetic and pharmacodynamic modeling of hedgehog inhibitor TAK-441 for the inhibition of Gli1 messenger RNA expression and antitumor efficacy in xenografted tumor model mice.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gene Expression; Hedgehog Proteins; Humans; Mice; Models, Biological; Neoplasms; Oncogene Proteins; Pyridines; Pyrroles; RNA, Messenger; Skin; Trans-Activators; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2013 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
Interleukin-2 and cancer: critical analysis of results, problems and expectations.
Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2 | 2003 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomedical Research; Drug Design; Drug Industry; Drugs, Investigational; Endothelial Growth Factors; Erlotinib Hydrochloride; Germany; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasms; Pyrroles; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells | 2003 |
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Ligands; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Mouth Neoplasms; Neoplasms; Paclitaxel; Phosphorylation; Propidium; Pyrimidines; Pyrroles; Tongue; Tongue Neoplasms; Tyrosine | 2003 |
Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Neoplasms; Pyrroles; Thromboembolism; Thrombophilia; Treatment Outcome | 2003 |
THE HUMAN TUMOR-EGG HOST SYSTEM. III. TUMOR-INHIBITORY PROPERTIES OF TENUAZONIE ACID.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspergillus; Azaserine; Carcinoma, Bronchogenic; Chick Embryo; Glycine; Mercaptopurine; Neoplasms; Neoplasms, Experimental; Puromycin; Pyrroles; Research; Saccharomyces; Tissue Culture Techniques; Triethylenemelamine | 1964 |
THE METABOLISM AND EXCRETION OF CO57 TETRAPHENYLPORPHINESULFONATE IN CANCER PATIENTS.
Topics: Abdominal Neoplasms; Brain Neoplasms; Cobalt Isotopes; Humans; Metabolism; Neoplasms; Pyrroles; Radiometry | 1964 |
PORPHOBILINOGEN AND DELTA-AMINOLEVULINIC ACID EXCRETION IN MULTIPLE SCLEROSIS.
Topics: Amino Acids; Aminolevulinic Acid; Demyelinating Diseases; Diagnosis, Differential; Fluids and Secretions; Humans; Levulinic Acids; Multiple Sclerosis; Neoplasms; Poliomyelitis; Porphobilinogen; Porphyrias; Porphyrins; Pyrroles; Urine | 1965 |
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Topics: Binding Sites; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Inhibitors; Hepatocyte Growth Factor; Humans; Indoles; Models, Molecular; Neoplasm Invasiveness; Neoplasms; Phosphorylation; Phosphotyrosine; Protein Conformation; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction | 2003 |
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Movement; Cell Survival; Drug Synergism; Endostatins; Endothelium, Vascular; Female; Glioblastoma; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrroles; Ultrasonography; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2003 |
C-H to N substitution dramatically alters the sequence-specific DNA alkylation, cytotoxicity, and expression of human cancer cell lines.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Cell Line, Tumor; DNA, Neoplasm; Duocarmycins; Humans; Imidazoles; Neoplasms; Nylons; Pyrroles; Pyrrolidinones; Structure-Activity Relationship; Substrate Specificity | 2004 |
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Topics: Antineoplastic Agents; Bone Marrow; Enzyme Inhibitors; Flow Cytometry; Gene Expression Profiling; Hematologic Neoplasms; Humans; Insulin-Like Growth Factor I; Multiple Myeloma; Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Glutamates; Guanine; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pemetrexed; Protein-Tyrosine Kinases; Pyrroles; Tumor Stem Cell Assay | 2004 |
Spectral characteristics of the supramolecular complexes of polypyrrolic sensitizers and cyclodextrin carriers: usage in photodynamic therapy of tumors.
Topics: Cyclodextrins; Drug Carriers; Neoplasms; Photochemistry; Photochemotherapy; Polymers; Porphyrins; Pyrroles; Radiation-Sensitizing Agents; Spectrometry, Fluorescence; Spectrophotometry | 2004 |
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
Topics: Aminoquinolines; Aniline Compounds; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Indoles; Kinetics; Morpholines; Mutation; Naphthalenes; Neoplasms; Oncogene Proteins v-abl; Organic Chemicals; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyrroles; Sunitinib | 2005 |
Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer.
Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Genes, myc; Humans; Indoles; Models, Animal; Neoplasms; Nitrophenols; Oncogenes; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyrroles; Sulfonamides | 2005 |
New targets, therapies, and toxicities: lessons to be learned.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2006 |
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
Topics: Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepinones; Clinical Trials, Phase I as Topic; ErbB Receptors; Humans; Neoplasms; Ornithine; Pterins; Pyrroles; Receptor, EphA2; Societies, Scientific | 2006 |
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A | 2006 |
Antitumor activity of sequence-specific alkylating agents: pyrolle-imidazole CBI conjugates with indole linker.
Topics: Adenine; Alkylation; Animals; Antineoplastic Agents, Alkylating; Base Sequence; Cell Line, Tumor; Cyclopropanes; Humans; Imidazoles; Indoles; Models, Molecular; Molecular Sequence Data; Molecular Structure; Neoplasms; Nucleic Acid Conformation; Nylons; Polymerase Chain Reaction; Pyrroles; Thymine | 2006 |
Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.
Topics: Alkylating Agents; Antibodies; Cell Line, Tumor; Drug Delivery Systems; Duocarmycins; Humans; Indoles; Neoplasms; Prodrugs; Pyrroles; Streptomyces; Tumor Stem Cell Assay | 2006 |
Sequence-specific alkylation of double-strand human telomere repeat sequence by pyrrole-imidazole polyamides with indole linkers.
Topics: Alkylation; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Indoles; Molecular Sequence Data; Neoplasms; Pyrroles; Repetitive Sequences, Nucleic Acid; Substrate Specificity; Telomere | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Immunity, Cellular; Neoplasms; Pyrroles; T-Lymphocytes | 2006 |
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Endothelium, Vascular; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta | 2007 |
[Anti-angiogenetic agents for solid tumors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Transformation, Neoplastic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib malate and multiple receptor tyrosine kinases inhibitors: are they also novel drugs for chronic and neurophatic pain?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Pain; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Signal Transduction; Sunitinib | 2007 |
5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Inhibitory Concentration 50; Insecta; Models, Chemical; Neoplasm Transplantation; Neoplasms; Piperidines; Pyrroles; Receptor, ErbB-2; Triazines | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome | 2007 |
Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.
Topics: Antineoplastic Agents; Humans; Indoles; Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptors, Cell Surface; Sunitinib | 2007 |
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Topics: Angiogenesis Inducing Agents; Animals; Antineoplastic Agents; Blood Proteins; Cell Hypoxia; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Mice; Mice, SCID; Neoplasms; Organ Specificity; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Pyrroles; Sunitinib; Thyroid Hormones | 2007 |
BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.
Topics: Apoptosis; Cell Line, Tumor; HL-60 Cells; Humans; K562 Cells; Mitosis; Neoplasms; Oxazepines; Protein Serine-Threonine Kinases; Pyrroles; Spindle Apparatus; Tubulin | 2008 |
Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells.
Topics: Aneugens; Animals; Aurora Kinase A; Aurora Kinases; Cell Survival; Genes, p53; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiation-Sensitizing Agents; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2007 |
Cardiac toxicity of sunitinib.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2007 |
Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genomic Imprinting; Insulin-Like Growth Factor II; Mice; Mice, Inbred C57BL; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Pyrroles; Signal Transduction | 2007 |
Synthesis of 1,2,3-triazole-linked pyrrolobenzodiazepine conjugates employing 'click' chemistry: DNA-binding affinity and anticancer activity.
Topics: Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; DNA; Humans; Kinetics; Neoplasms; Pyrroles; Triazoles | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles | 2008 |
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2008 |
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib | 2008 |
Molecule of the month. Elesclomol and obatoclax mesylate.
Topics: Antineoplastic Agents; Controlled Clinical Trials as Topic; Humans; Hydrazines; Indoles; Melanoma; Neoplasm Metastasis; Neoplasms; Pyrroles | 2008 |
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Lactones; Neoplasms; NF-kappa B; Protease Inhibitors; Pyrazines; Pyrroles; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Up-Regulation; YY1 Transcription Factor | 2008 |
Statins, leptin and regulatory T cells.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness | 2008 |
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2008 |
Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyrroles; Pyrrolidines; Transplantation, Heterologous | 1982 |
A hypothesis for dietary components as blocking agents of chemical carcinogenesis: plant phenolics and pyrrole pigments.
Topics: Animals; Carcinogens; Diet; Glycosides; Humans; Neoplasms; Phenols; Pyrroles; Structure-Activity Relationship | 1984 |
Skin sensitization with the new reagents NOPYE (4-nitro-1-cyclohexyl-3-ethoxy-2-oxo-3-pyrroline) and NOPY-L-phenylalanine.
Topics: Adjuvants, Immunologic; Animals; Cross Reactions; Cyclohexanes; Dinitrochlorobenzene; Female; Guinea Pigs; Hypersensitivity, Delayed; Immunotherapy; Neoplasms; Ovalbumin; Phenylalanine; Pyrroles; Skin; Tuberculin | 1980 |
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
Topics: 3T3 Cells; Animals; Cell Division; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Female; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Time Factors | 1998 |
Researchers describe findings for targeted cancer therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Division; Cetuximab; Clinical Trials as Topic; Endothelial Growth Factors; ErbB Receptors; Humans; Indoles; Lymphokines; Neoplasms; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Fenretinide; Guanine; Humans; Indoles; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Pyrrolo[2,1-c][1,2,4]triazines from 2-diazopyrroles: synthesis and antiproliferative activity.
Topics: Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives.
Topics: Alkylating Agents; Animals; Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Circular Dichroism; Distamycins; DNA; Humans; Leukemia L1210; Leukemia, Experimental; Mice; Neoplasms; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1989 |
Synthesis and antineoplastic activity of 5-aryl-2,3-dihydropyrrolo[2,1-b]thiazole-6,7-dimethanol 6,7-bis(isopropylcarbamates).
Topics: Carbamates; Cell Division; Cell Survival; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; Leukemia, Myeloid; Neoplasms; Pyrroles; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 1988 |
Nature of distamycin A-inducible fragile sites.
Topics: Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Distamycins; Female; Genetic Markers; Humans; Karyotyping; Male; Neoplasms; Pedigree; Pyrroles; Tumor Cells, Cultured | 1988 |
Distamycin A-inducible fragile sites and cancer proneness.
Topics: Chromosome Fragile Sites; Chromosome Fragility; Disease Susceptibility; Distamycins; Female; Humans; Karyotyping; Male; Neoplasms; Pyrroles; Tumor Cells, Cultured | 1988 |
Familial fragile site found at the cancer breakpoint (1)(q32). Inducibility by distamycin A, concomitance with fragile (16)(q22).
Topics: Cells, Cultured; Chromosome Banding; Chromosome Fragile Sites; Chromosome Fragility; Chromosomes, Human, 1-3; Chromosomes, Human, 16-18; Distamycins; Female; Genetic Markers; Humans; Infant, Newborn; Intellectual Disability; Karyotyping; Male; Neoplasms; Pyrroles | 1986 |
Studies on the effects of chemicals on the processing of nuclear RNA. Some possible implications with respect to carcinogenesis.
Topics: Adenine Nucleotides; Animals; Antibiotics, Antineoplastic; Benzazepines; Carcinoma, Ehrlich Tumor; Cell Line; Cell Nucleus; Dactinomycin; Daunorubicin; Drug Stability; Neoplasms; Plicamycin; Polynucleotides; Pyrroles; Ribonucleases; RNA | 1971 |
Structural requirements for nicotine and cyclic imine-induced amine release from neoplastic mast cells.
Topics: Amines; Animals; Azetines; Azirines; Cell Line; Chemical Phenomena; Chemistry; Electrons; Hydrogen-Ion Concentration; Imidazoles; Imines; Kinetics; Mast Cells; Mice; Mice, Inbred Strains; Neoplasms; Nicotine; Piperidines; Pyrroles; Pyrrolidines; Serotonin; Solubility; Spectrometry, Fluorescence; Structure-Activity Relationship | 1974 |